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ABSTRACT 
HSP70 plays an important role in cancer development. However, the molecular 
role of HSP70 in cancer is poorly understood.  Previous work from our laboratory 
demonstrated that HSP70 is essential for initiation of Her2-positive breast cancer by 
controlling oncogene-induced senescence. Here we demonstrate that HSP70 is critical for 
both initiation and progression of mammary cancer. Interestingly, the role of HSP70 in 
cancer development did not involve its canonical function as a molecular chaperone.  
Instead, HSP70 had multiple effects on signaling pathway components related to tumor 
initiation, growth, and metastasis, such as FOXM1, HIF1, NF-κB, and SRC. HSP70 
regulated signaling networks via association with the co-chaperone, BAG3, a scaffold 
protein with capacity to interact with multiple key regulators of cell signaling. Using SRC 
as a model, we demonstrated that association with HSP70 attenuates BAG3’s interaction 
with the SH3 domain of SRC. We also show that an HSP70-interacting small molecule, 
YM-1, can specifically inhibit the HSP70-BAG3 signaling axis, leading to selective 
inhibition of tumor growth in vivo and in vitro. This compound mimicked the effects 
 x 
 
seen with depletion of HSP70 in a dose dependent manner, providing a proof of principle 
that the association of HSP70 and BAG3 is needed for regulation of these pathways. 
Additionally, a second generation of YM-1 analogs, JG-98 and JG-84, were shown to be 
more potent than YM-1 while acting in a similar fashion on signaling pathways. A less 
potent analog, JG-36, was not able to modulate these pathways as effectively.  These 
studies demonstrate that the HSP70-BAG3 axis is a major regulator of cancer signaling 
and suggest that targeting the interface between HSP70 and BAG3 is a novel therapeutic 
approach.  
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Chapter I.   Introduction 
1. Heat Shock Response, Heat Shock Factors, and Heat Shock Proteins 
A. Overview 
 
The ability to adapt to changing environmental conditions is important on both an 
organismal and microscopic level. Cells must be able to manage and endure changes in 
their microenvironment, such as fluctuations in temperature. The heat shock response 
(HSR) is a response to stress that has been highly conserved across kingdoms from 
bacteria to mammals, suggesting that the response is vital for survival in challenging 
environments. 
B. Heat Shock Response 
 
In the 1960s, Ferruccia Ritossa was working with Drosophila salivary glands 
when he noticed a different chromosomal puffing pattern, indicative of locally enhanced 
transcription, in polytene chromosomes after thermal stress (Ritossa, 1962). This 
discovery led to an entirely new avenue of scientific research exploring the HSR and the 
resultant induction of proteins, dubbed heat shock proteins (HSPs) (McAlister et al, 1979; 
Peterson et al, 1979; Tissières et al, 1974). The HSR has since been characterized as a 
well ordered and highly regulated cellular response to stress that protects the cell by 
conferring tolerance to conditions that would otherwise be lethal (Li & Werb, 1982; 
Riabowol et al, 1988; Subjeck et al, 1982). Moreover, the response is not confined to 
hyperthermic conditions, but can also be triggered by other stressors such as oxidative 
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stress and exposure to toxic compounds, suggesting that the HSR is a general stress 
sensor (Cajone & Bernelli-Zazzera, 1988; Courgeon et al, 1984; Li, 1983).  
Genome wide analysis of the stress response in a variety of cells and organisms 
suggests that the HSR targets nearly 3% of the genome, inducing expression of some 
genes and repressing others(Gasch et al, 2000; Hahn et al, 2004; Murray et al, 2004; 
Tabuchi et al, 2008; Trinklein et al, 2004). Review of approximately 200 genes induced 
by the stress response were found to fall into seven different categories including: 
molecular chaperones, proteolytic machinery, RNA/DNA-modifying enzymes, metabolic 
enzymes, transcription factors and kinases for signaling cascades, maintenance of cellular 
structures, and proteins involved in transport, detoxification, or membrane 
modulation(Richter et al, 2010). See Figure 1 for the relative proportion of proteins in 
each class produced during the heat shock response. 
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Figure 1. Classifications of Heat Shock Response Proteins. 
The relative proportion of each class is shown. Adapted from (Richter et al, 2010).  
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C. Heat Shock Factor 
 
Heat shock transcription factors (HSFs) regulate the HSR. HSFs bind to cis-acting 
sequences, referred to as heat shock elements (HSEs), upstream of target genes involved 
in the heat shock response. The HSE has been characterized to be an array of inverted 
repeats of the n-GAA-n motif (Akerfelt et al, 2010; Pelham, 1982; Trinklein et al, 2004). 
Four HSF homologs have been identified, but human cells express only three members of 
the HSF family-- HSF1, HSF2, and HSF4. While all three are involved in the heat shock 
response, HSF1 is considered the master regulator and will be focused on here (for 
review see Akerfelt et al 2010).  
During heat shock, the cell does not recognize temperature per se, but rather the 
HSR is triggered by unfolded proteins. Slight increases in temperature above routine can 
trigger protein denaturation and potentially toxic aggregation. Under normal physiologic 
conditions HSF1 is located in the cytosol as a monomer in complex with heat shock 
protein 90 (HSP90) and heat shock protein 70 (HSP70) (Figure 2). When unfolded 
proteins are present, as under heat shock conditions, HSP90 and HSP70 are titrated away 
from HSF1 to assist with damaged proteins, and HSF1 is able to trimerize (Rodriguez et 
al, 2008). Full activation of HSF1 requires translocation of the HSF1 trimers into the 
nucleus, as well as significant posttranslational modification, including multisite 
phosphorylation (Baler et al, 1996; Cotto et al, 1996; Cotto & Morimoto, 1999; 
Guettouche et al, 2005; Kline & Morimoto, 1997; Pirkkala et al, 2001; Shamovsky & 
Nudler, 2008; Trinklein et al, 2004; Voellmy, 1996).  
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Figure 2. Regulation of HSF1 Activation. 
 
Under normal conditions HSF1 is found in monomeric form in the cytosol in complex 
with HSP70 and HSP90. Upon stress, HSF1 is released from complex, phosphorylated, 
trimerizes, and translocates to the nucleus. Further phosphorylation steps are required for 
HSF1 binding to HSE promoter elements in order to recruit RNA polymerase and active 
transcription of stress responsive genes. Adapted from (Richter et al, 2010). 
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D. Heat Shock Proteins 
 
Heat shock proteins (HSPs) are a set of highly conserved proteins whose 
expression can be transiently induced by stress conditions (Tissières et al, 1974). Initially 
HSP expression was associated with heat shock, but their induction can be triggered by 
any insult resulting in protein damage such as oxidative stress, irradiation, or toxic 
compounds (Cajone & Bernelli-Zazzera, 1988; Courgeon et al, 1984; Drummond & 
Steinhardt, 1987; Li, 1983). Acute or chronic stress results in protein misfolding, protein 
aggregation, and disruption of regulatory complexes. HSPs have been generally 
characterized as molecular chaperones that associate with other cellular proteins to assist 
in folding and to prevent protein aggregation, and are therefore thought to maintain 
protein homeostasis (Lindquist & Craig, 1988). HSPs are classified into six families 
based on molecular size: HSP110, HSP90, HSP70, HSP60, HSP40, and small HSPs, and 
can be found various sub-cellular compartments (see Table 1 for summary) (Hartl, 2002; 
Lindquist & Craig, 1988; Saibil, 2013). The chaperone activity of high molecular weight 
HSPs is ATP-dependent, while small HSPs act in an ATP-independent fashion. In 
addition to their universal role in maintaining protein homeostasis, certain HSPs have 
been shown to be critical to signaling pathways. For example, HSP90 regulates steroid 
receptors, e.g. the estrogen and progesterone receptors, as well as transcription factors 
like STAT3 and OCT4, and kinases such as HER2, c-SRC, RAF-1, and AKT, among 
others (Bradley et al, 2012; Gasc et al, 1990; Prinsloo et al, 2012; Sato et al, 2000; 
Schlatter et al, 1992; Stancato et al, 1993; Xu et al, 2001; Xu et al, 1999).  
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Table 1. Classes of Heat Shock Proteins 
Family Location
Prokaryotic 
Homolog
Comments
Hsp110
Cytosol                    
Nucleus
ClpA, ClpB, 
ClpX
Severe stress tolerance
Hsp90
Cytosol        
Nucleus              
Mitochondria
HtpG
Binding, stabilization, and maturation of 
steroid receptors, protein kinases, and 
other signaling proteins
Hsp70
Cytosol           
Nucleus             
Mitochondria            
ER
DnaK
Refolding/Unfolding                    
Disaggregation                                       
Targeting of substrates for degradation
Chaperonins:    
Hsp60                 
CCT
                        
Mitochondria                
Cytosol
GroEL Molecular chaperone
Hsp40 Cytosol DnaJ Hsp70 co-chaperone
small Hsps:        
Hsp20-30                         
Hsp10
Cytosol/Nucleus             
Mitochondria
GrpE                     
GrpES
Form oligomers  and                                  
prevent aggregation
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E. HSP70 Family of Molecular Chaperones 
 Overview i.
 
HSP70 proteins are ubiquitously expressed ATP-dependent molecular 
chaperones. They are also extremely conserved in evolution; HSP70 can be found in all 
organisms from archaebacteria and plants to humans (Lindquist & Craig, 1988). This 
conservation is reflected by the preserved functional properties of the different HSP70 
homologs across species. For example, the D. melanogaster HSP70, when expressed in 
mammalian cells, can protect them against heat stress (Pelham, 1984). 
 The HSP70 Family ii.
 
The human family of HSP70 contains eight gene products that differ by amino 
acid sequence, expression level, and cellular localization (see Table 2). Each member of 
the family may have several aliases, which are used interchangeably. Cytosolic versions 
of HSP70 include the major stress inducible HSP70, the constitutively expressed HSC70, 
as well as more minor members: HSP70-1t, HSP70-2, and HSP70-6.  Additionally, 
certain cellular compartments also have their own HSP70 member; mtHSP75 (Grp75, 
mortalin) is localized to the mitochondrial matrix, and BiP (Grp78) is found in the ER.  
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Table 2. The Human HSP70 Family of Proteins 
Protein Aliases
Homology 
to Hsp70-1a 
(%)
Gene
Chromosomal 
Localization
Cellular 
Localization
Tissue 
Expression
Stress-
Induced
Hsp70
Hsp70, 
Hsp72, 
Hsp70-1
100                           
99
HSPA1A
HSPA1B
6p21.3
Cytosol, 
Nucleus, 
Lysosomes
Ubiquitous Yes
Hsp70-1t
Hsp70-
hom
91 HSPA1L 6p21.3
Cytosol, 
Nucleus, 
testes No
Hsp70-2
Hsp70-2, 
HspA2
84 HSPA2 14q24.1 Cytosol, Nucleus
brain,      
testes
No
Bip
Hsp70-5, 
Grp78
64 HSPA5 9q33-q34.1 ER Ubiquitous No
Hsp70-6 Hsp70B' 85 HSPA6 1q23.3 Cytosol, Nucleus blood, immune Yes
Hsc70
Hsp73, 
Hsc73, 
Hsp70-8
86 HSPA8 11q23.3-q25 Cytosol, Nucleus Ubiquitous No
Mortalin
Hsp70-9, 
Grp75, 
mtHsp75
52 HSPA9 5q31.1
Mitochondria, 
Perinuclear 
Cytosol
Ubiquitous No
 
Adapted from (Daugaard et al, 2007). 
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 HSP70 Structure iii.
 
Since HSP70s are so well conserved (68% homology between the E.coli HSP70 
and human HSC70), studies using an HSP70 from one organism are accepted to 
approximate the behavior of the others. The E. coli HSP70 ortholog, DnaK, is one of the 
best studied and is primarily used to discuss general properties of HSP70 (Zuiderweg et 
al, 2013). DnaK contains multiple domains (see Figure 3): 1) An N-terminal nucleotide 
binding domain (NBD) of about 45kDa. The NBD is subdivided into four subdomains: 
IA, IB, IIA, and IIB. IA-IB and IIA-IIB form the two arms of a V-shaped cleft where 
ATP is bound and hydrolyzed. 2) The NBD is connected via a highly conserved protease 
sensitive linker of about 10-12 residues to the substrate binding domain (SBD). 3) The 
SBD is a beta-basket of 13kDa made up of 2 antiparallel beta sheets. Client proteins with 
exposed hydrophobic residues bind to hydrophobic pocket located between the two beta 
sheets. A short linker connects the SBD to an alpha helical “lid”, which is thought to 
shield the substrate binding pocket. 5. Finally, the tail region of the SBD extends beyond 
the lid by approximately 50 residues. The last four amino acids of the tail comprise an 
EEVD (amino acid designations) motif that is essential for HSP70’s chaperone function, 
as well as for interaction with tetratricopeptide repeat domain containing proteins. Recent 
work suggests that the tail may act to enhance chaperone function by transiently 
interacting with folding clients (Murphy, 2013; Saibil, 2013; Zuiderweg et al, 2013) . 
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Figure 3. The Structure of HSP70. 
(a) Schematic of HSP70 domains. Adapted from (Daugaard et al, 2007).  (b) The solution 
structure of E. coli DnaK. Adapted from (Murphy, 2013).  
 
  
a. 
b. 
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 HSP70 Co-chaperones and the HSP70 Refolding Cycle iv.
 
HSP70 is canonically described as a protein unfolding machine, which binds and 
releases stretches of hydrophobic amino acids in a regulated, ATP-hydrolysis-driven 
cycle. HSP70 maintains the levels of free unfolded client low enough to prevent 
aggregation through stable “holding” of the client (Calderwood, 2013; Zuiderweg et al, 
2013). Additionally, HSP70 is thought to induce local unfolding in client protein 
domains, helping to lower kinetic barriers to the native folded state, and assist in substrate 
refolding (Calderwood, 2013; Mayer et al, 2000). Besides playing a major role in protein 
folding, HSP70s are able to direct irreversibly denatured proteins to degradation via the 
ubiquitin-proteasome system or by the lysosomal proteolysis system (Bercovich et al, 
1997; Chiang et al, 1989; Nylandsted et al, 2004; Sherman & Goldberg, 1996; Terlecky 
et al, 1992). Alone, the ATP hydrolysis rate of HSP70 is slow, and co-chaperones are 
critical in increasing the hydrolysis and ADP-ATP exchange rates (Russell et al, 1998). 
For example, members of the HSP40 family (also call J-domain proteins) bind to the 
NBD of HSP70 and stimulate its ATPase activity (Laufen et al, 1999). Other co-
chaperones that bind to the NBD, like Bag proteins, are nucleotide exchange factors 
(NEFs) that catalyze the release of adenosine diphosphate (ADP), and allows for 
substrate release (Bukau et al, 2006; Calderwood, 2013). Finally, a third class of co-
chaperones, CHIP and HOP, bind to the C terminus of HSP70 and mediate fate of 
substrates (Bukau et al, 2006; Calderwood, 2013; McDonough & Patterson, 2003; 
Murphy, 2013; Wegele et al, 2006).  
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HSP40 proteins contain a J domain, which is capable of interacting with the ATP 
domain of the HSP70s, and a client binding domain that can associate with unfolded 
proteins.  In its “empty” state, HSP70 contains ATP in associated with the NBD, and in 
this form SBD can interact with unfolded clients (see Figure 4a). HSP40 co-chaperones 
recognize and bind to unfolded substrates and escort them to the “empty” HSP70 protein 
(see Figure 4b). Peptide binding to the HSP70 SBD induces a conformational change that 
is propagated back to the NBD, which, along with association of the HSP40 J domain, 
stimulates ATP hydrolysis. Hydrolysis of ATP to ADP by the NBD is then signaled back 
to the SBD, resulting in closing of the alpha-helical lid and enhanced client binding (see 
Figure 4a and b).  
Following this “holding” stage, the next step is client release and potential 
refolding.  In order for HSP70 to release clients, ADP must dissociate from the N-
terminal domain. Bag proteins contain a conserved Bag domain, which interacts with the 
ATPase domain of HSP70 and stimulate ADP release. This allows for opening of the 
SBD and subsequent discharge of the client protein (see Figure 4b) (Bukau et al, 2006; 
Calderwood, 2013; Murphy, 2013; Saibil, 2013).  
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Figure 4. HSP70 Chaperone Cycle 
 (a) Left- ADP-bound form of HSP70 in closed conformation. Note position of lid 
domain (red) over the substrate binding pocket (blue) locking the substrate (yellow) in 
place. Right- In the ATP-bound form, the lid is in the open conformation and substrate is 
freed. A corresponding cartoon is shown below the structures. Adapted from Saibil et al. 
2013. (b) Cartoon of the HSP70 chaperone cycle with HSP40, substrate polypeptide, a 
NEF, and ATP-ADP. ATP hydrolysis is facilitated by HSP40 and results in closing of the 
HSP70 lid and increased affinity for the substrate. NEFs mediate ADP release and 
substrate release. Adapted from (Murphy, 2013; Saibil, 2013). 
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HSP70 also contains a TPR domain binding (TDB) site at the extreme C-
terminus. The TPR (tetratricopeptide repeat) domain is a protein interaction motif found 
in a range of proteins, many of which interact with HSP70 and HSP90 (Calderwood, 
2013; Murphy, 2013; Zuiderweg et al, 2013). In the case of HSP70, such TPR domain 
proteins include Hop (HSP70/HSP90 organizing protein) and the ubiquitin E3 ligase, 
CHIP. HOP is a tetratricopeptide repeat domain protein that couples the interaction of 
HSP70 with HSP90 (Frydman & Hohfeld, 1997; Scheufler et al, 2000; Wegele et al, 
2006). When HSP70 binds to its TPR domain on Hop, HSP90 can also bind to another 
TPR motif. Such coupling permits a coordinated pathway of remodeling of some clients 
with initial folding of nascent proteins by HSP70/HSP40 complexes, preceding to fine 
tuning of client conformation by HSP90 (Frydman & Hohfeld, 1997; Scheufler et al, 
2000; Wegele et al, 2006). Alternatively, protein quality control can be biased towards 
proteolysis and disposal of damaged proteins when the E3 ligase CHIP binds the TBD 
motifs HSP70. CHIP inhibits the HSP40 stimulated ATPase activity of HSP70 and by 
virtue of its E3-ubiquitin ligase activity is believed to re-focus HSP70 to direct misfolded 
proteins for ubiquitination and degradation instead of refolding (Fan et al, 2005; 
McDonough & Patterson, 2003; Murata et al, 2001; Sha et al, 2009; Wiederkehr et al, 
2002). Triage of client proteins between folding and degradation is therefore dependent 
on the combination HSP70 cofactors available. 
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 Cytosolic HSP70 Family Members v.
 
HSP70 accumulation is associated with tolerance to variety of stressors, including 
hyperthermia, hypoxia, ischemia, acidosis, cytokines such as tumor necrosis factor-α 
(TNF-α), and ultraviolet (UV) radiation, and initial tolerance to one stress condition 
confers tolerance to other types (Bellmann et al, 1996; Brondani Da Rocha et al, 2004; 
Calderwood & Asea, 2002; Chi & Mestril, 1996; Ciocca et al, 1992; Craig, 1989; Iwaki 
et al, 1993; Jaatella, 1992; Jaattela, 1993; Kampinga et al, 1995; Marber, 1995; Mestril et 
al, 1994; Mestril et al, 1996; Solomon et al, 1991). In stressed human cells, the HSP70 
isoforms account for roughly 2% of all protein mass (Zuiderweg et al, 2013). It has been 
demonstrated that the chaperone function of HSP70 is required for its cytoprotecitve 
effect and the development of stress tolerance (Riabowol et al, 1988). Elevated levels of 
HSP70 under stress conditions allow cells to manage increased concentrations of 
unfolded or aggregated proteins and thereby avoid cell death related to proteotoxicity. 
Finally, HSP70 has been shown to be anti-apoptotic at multiple points in the apoptotic 
signaling pathway, which will be discussed later.  
The major stress-inducible protein HSP70 isoform is encoded by closely linked 
intron-less genes, HSPA1A and HSPA1B, which are found in the major histocompatibility 
class (MHC) III cluster between the complement and TNF loci on chromosome 6. These 
two genes encode HSP70-1a and HSP70-1b, which are more than 99% identical (sharing 
all but 2 of their 641 amino acids), and so collectively are called HSP70 (see Figure 5). 
During stress conditions, both HSP70 genes are activated by binding of HSF1 to HSEs 
found in multiple copies in the 5’ promoter region (Park & Craig, 1989; Park & Craig, 
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1991). To prevent confusion due to nomenclature and multiple HSP70s, from here on 
mention of HSP70 is referring to this member of the HSP70 family 
HSP70 may also be expressed under normal conditions; both promoters also 
contain several binding sites for basal transcription factors such as TATA factor, 
CCAAT-box binding transcription factors, and SP1 (Greene & Kingston, 1990; Morgan, 
1989; Morgan et al, 1987). Basal expression of HSPA1A and HSPA1B mRNA differs 
with tissue specificity though HSPA1A is expressed somewhat higher than HSPA1B in 
most tissues and cell types (Daugaard et al, 2007).  
Mice deficient of the equivalent murine proteins, HSP70.1 or HSP70.3 are viable 
and fertile, but display increased sensitivity to pancreatitis, UV irradiation, osmotic 
stress, ischemia, and reduced capacity to acquire resistance to inflammatory shock after 
preconditioning with heat (Huang et al, 2001; Hwang et al, 2005; Kwon et al, 2002; Lee 
et al, 2001; Shim et al, 2002; Van Molle et al, 2002). Mice deficient in both HSP70.1 and 
HSP70.3 are also viable and fertile, but are sensitized to sepsis and have reduced capacity 
to develop tolerance to cardiac ischemia (Hampton et al, 2003; Hunt et al, 2004; 
Singleton & Wischmeyer, 2006).  Cells isolated from these mice display genomic 
instability and increased sensitivity to radiation (Hunt et al, 2004). Table 3 summarizes 
the known effects of HSP70 family member knock out in mouse models.  
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Figure 5. 
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Figure 5. HSP70 family protein alignment.   
From sequences NM_005345 (HSP701-a), NM_005346 (HSP701-b), NM_005527 
(HSP70-1t), NM_021979 (HSP70-2), NM_002155 (HSP70-6), NM_006597 (HSC70), 
NM_005347 (HSP70-5), and NM_004134 (HSP70-9). Black squares indicate homology 
gray square indicate changes in functionally conserved amino acids. White squares 
indicate functionally non-conserved amino acid disagreement. Adapted from (Daugaard 
et al, 2007). 
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Table 3. Phenotypes of HSP70 Knockout Mice 
Protein
Mouse 
Gene
Human 
Analog
Phenotype Ref
Hsp70.1 Hspa1a HSPA1A
Viable and fertile. Susceptible to UV, 
ischemica, TNF, pancreatitis, and heat 
Lee, et al 2001,        
Van Molle et al 2001, 
Kwon et al 2002, 
Hwang et al 2005
Hsp70.3 Hspa1b HSPA1B Viable and fertile. Suceptible to heat. Huang et al 2001
Hsp70.1 + 
Hsp70.3
Hspa1a + 
Hspa1b
HSPA1A + 
HSPA1B
Viable and fetile. Suceptible to 
radiation and sepsis.                                      
Increased genomic instability
Hampton et al 2003, 
Hunt et al 2004, 
Singleton et al 2006
Hsp70.2 Hspa2 HSPA2
Viable and fertile females.           
Meiotic defects in male germline cells
Dix et al 1996,          
Zhu et al 1997,          
Dix et al 1997
Hsc70 Hspa8 HSPA8
Not applicable.                                
Knockout cell non-viable
Florin et al 2004
BiP Hspa5 HSPA5 Embryonically lethal day 3. 5 Luo et al 2006
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While some HSP70 is produced under basal conditions, the majority of the cell’s 
chaperone needs are met by the cognate HSC70 (HSP70-1, HSP73). HSC70 is the 
constitutive form of HSP70 expressed in most tissues, and is encoded by the HSPA8 
gene; it is 85% identical to HSP70 (see Figure 5) (Daugaard et al, 2007). HSC70 has been 
described to have a multitude of housekeeping chaperoning functions from folding of 
nascent polypeptides, to protein translocation to the nucleus, to chaperone-mediated 
autophagy, to disassembly of clatherin-coated vesicles (Bukau et al, 2006; Lindquist & 
Craig, 1988).  Knockdown of HSC70 using RNAi results in massive cell death in various 
cell types. (Rohde et al, 2005b) 
Though highly homologous, HSC70 and HSP70 do not necessarily perform the 
same functions. HSP70 and HSC70 have different expression patterns; HSC70 is 
constitutively expressed and only mildly induced during stress situations, where HSP70 is 
highly inducible. The most significant differences between the two are found in the C-
terminal domain which is involved in recognizing substrate (Figure 5). In terms of 
functionality, both can influence intracellular trafficking of ion channels, but to different 
ends. HSC70 has been found to decrease the surface expression and performance of 
murine epithelial sodium channels. However, HSP70 has the opposite effects on the same 
channel (Goldfarb et al, 2006). Alternatively, HSP70 and HSC70 both interact with lipid 
bilayers, but HSC70 has a more dramatic effect on promoting polypeptide translocation 
and membrane protein folding (Arispe et al, 2002). Additionally, it was recently found 
that HSP70 is more sensitive to oxidation than HSC70 and this sensitivity was correlated 
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with increased tau clearance in the presence of an oxidizing substance, such as methylene 
blue (Miyata et al, 2012). 
The other cytoplasmic HSP70 family members include HSP70-1t, HSP70-2, and 
HSP70-6. These members are tissue specific and may or may not be stress inducible. For 
example, HSP70-1t is only found in the testes, HSP70-2 can be found in both testes and 
brain, and HSP70-6 is expressed in certain immune cells (Daugaard et al, 2007).  
 
 Other HSP70 Family Members vi.
 
BiP is the HSP70 counterpart found in the endoplasmic reticulum (ER). It is 
constitutively expressed and due to an N-terminal ER localization sequence and C-
terminal “KDEL” ER retention signal, is restricted to the lumen of the ER where it 
facilitates the transport of newly synthesized proteins and assists in their folding 
(Gething, 1999). BiP can be found in all cell types, but is highly expressed in secreting 
cells like the pancreatic islets (Gething, 1999). Due to its role in folding proteins within 
the ER, BiP is regarded as essential housekeeping gene, and so it is unsurprising that BiP 
knockout mice are embryonically lethal (see Table 3) (Luo et al, 2006).  
mtHSP75, also commonly referred to as mortalin, is considered the mitochondrial 
version of HSP70. The mtHSP75 gene, HSPA9, contains an N-terminal targeting signal 
which delivers mtHSP70 to mitochondrial matrix where it assists other incoming proteins 
in correct folding after the trans-membrane transport (Kaul et al, 2007). However, 
mortalin also has a substantial pool present in the cytosol in a perinuclear distribution.  
This cytosolic mtHSP75 has been shown to sequester the tumor suppressor, p53, in the 
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cytosol, inhibiting its activation and pro-apoptotic effects (Wadhwa et al, 1998). As with 
other members of the HSP family, mtHSP75 is also overexpressed in many cancers 
(Deocaris et al, 2013).  
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2. Oncogene Induced Senescence 
A. Overview 
 
Hayflick and Moorhead originally observed senescence in in 1961 when they 
found normal cells had a limited ability to proliferate in culture. It was proposed that “a 
factor necessary for cell survival” incrementally decreased to a threshold level which 
triggered senescence (Hayflick & Moorhead, 1961). This factor was later determined to 
be telomere length, and the threshold is now termed the Hayflick limit (Bodnar et al, 
1998; Harley et al, 1990).   
Senescence can be triggered by various stresses beyond telomere dysfunction 
including: DNA damage (single-stranded and double-strand breaks), oxidative insults 
(stress-induced or premature senescence), and in response to strong mitogenic signaling, 
such as those produced by certain oncogenes (Figure 6) (Rodier & Campisi, 2011). 
Senescence is one way in which aging cells exit the pool of replicating cells associated 
with tissue homeostasis. Instead of undergoing apoptosis these cells become permanently 
growth arrested (usually in the G1 phase of the cell cycle), but remain metabolically 
active and can survive in cell culture for extended periods of time (Campisi, 2013). The 
concept of senescence serving as a checkpoint, guarding against aberrant processes, has 
emerged as a key theory in a variety of diseases, notably in cancer (Braig & Schmitt, 
2006b).   
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Figure 6. Triggers and Markers of Senescence. 
 
Senescence can be induced in multiple circumstances as indicated. Markers of senescence 
include phenotypic changes, SA-β-gal staining (blue color), chromatin structure changes 
such as DNA Damage Foci (SCARS) and Heterochromatin Foci (SAHF), activation of 
p53 and increased expression of p21 and p16, and secretion of factors (SASP). Adapted 
from (Saretzki, 2010) and (Rodier & Campisi, 2011)  
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B. Senescence Markers  
 
Senescence is accompanied by a multitude of morphologic and physiologic 
changes (Figure 6). Morphologically, senescent cells acquire an enlarged, flattened, and 
vacuolated appearance (Hayflick & Moorhead, 1961).  Biochemically, they have a high 
degree of senescence associated β-galactosidase (SA-β-gal) activity at pH6.0 (Dimri et al, 
1995). The SA-β-gal assay is currently the gold standard for detecting senescent cells 
both in vitro and in vivo. The function of SA-β-gal in senescence remains unknown, but it 
is thought that the increased expression of SA-β-gal is associated with the expansion of 
lysosomes during senescence, which contain β-galactosidase as a lysosomal enzyme (Lee 
et al, 2006). However, there is some controversy with using only SA-β-gal as a marker of 
senescence as Sedivy et al found that the assay could not distinguish between cellular 
senescence and mitotic crisis in human fibroblasts (Wei & Sedivy, 1999).  Serrano et al. 
employed genetic screening approaches to find better indicators of senescent cells. Using 
microarray analysis of various cell lines, they were able to find additional markers such 
as decoy receptor 2 (Dcr2), differentiated embryochondrocyte expressed 1 (Dec1) and 
p15
INK4B
 that were up-regulated in senescent cells and were validated using mouse tumor 
models (Collado et al, 2005b; Collado & Serrano, 2006).  
Additionally, senescence is also associated with numerous chromatin changes, in 
particularly the formation of senescence-associated heterochromatin foci (SAHF) (Narita 
et al, 2003). The SAHF are formed in a p16-Rb-dependent manner, and are thought to 
repress E2F target genes required for cell proliferation. These foci can be assayed by 
staining for chromatin associated proteins such as HP1γ and HMGA, the presence of 
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histone variants (macroH2A), and modifications of histones such as histone H2 di- or tri-
methylated on lysine 9 (H3K9). Alternatively, as a result of persistent DNA damage 
response signaling, senescent cells may also harbor distinct foci (distinguishable from 
SAHF) called DNA-SCARS (DNA segments with chromatin alterations reinforcing 
senescence). These foci contain histone variant H2AX, as well as chromatin associated 
proteins such as MDC1 (but not the DNA repair RPA complexes or RAD51), and 
activated CHK2, to name a few (Rodier et al, 2011).  
Senescent cells are also known to secrete multiple factors including growth 
factors, proteases, cytokines, and chemokines, and this has been termed the senescence-
associated secretory phenotype (SASP) (Coppé et al, 2008).  
Finally, there are several proteins that are essential for senescence induction and 
maintenance that are also used as markers of senescence. Among these are p53, 
p21
Cip1/Waf1
, p16
INK4A
, and p19
ARF
, which mediate various components of the senescence 
program (Ben-Porath & Weinberg, 2005; Campisi, 2013; Ferbeyre et al, 2002; Gire et al, 
2004; Itahana et al, 2004; Mallette et al, 2007; Rodier & Campisi, 2011). 
 
C. Pathways Inducing Senescence 
 
Replicative senescence is classically associated with the DNA damage response 
(DDR), which is induced by loss of telomeric function (d'Adda di Fagagna et al, 2003). 
However, senescence in general can be triggered by any insult resulting in DNA damage, 
such as chemotherapies which induce double stranded breaks, or ionization (Mallette et 
al, 2007). Senescence resulting from DNA damage is usually driven primarily via the p53 
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pathway, of which the cyclin-dependent kinase (CDK) inhibitor, p21, is a crucial 
transcriptional target (Di Leonardo et al, 1994). 
Damaged DNA sites are recognized by sensor repair complexes in the nucleus, 
such as the replication protein A (RPA) and replication protein C (RPC) complexes, or 
the MRN complex (Figure 7)(Harper & Elledge, 2007). This leads to the activation of 
ATM (ataxia telangiectasia mutated) and ATR (ATM-Rad-3 related) kinases, which 
phosphorylate histone variant H2AX and result in its localization to the site of damage 
(Bartek et al, 2007). This in turn recruits several DDR intermediary proteins, MDC1, 
53BP1, and BRCA1, which are also phosphorylated by ATM or ATR (Campisi & d'Adda 
di Fagagna, 2007; Harper & Elledge, 2007). These adaptor proteins facilitate the 
recruitment of CHK1 and CHK2 (Figure 7). In normally growing cells, p53 levels are 
low due to its interaction with HDM2, which targets p53 for nuclear export and 
proteasomal degradation in the cytoplasm (Michael & Oren, 2003). Chk1/Chk2 
phosphorylate p53, inhibiting the p53-MDM2 interaction, and resulting in p53 
stabilization, activation, and the elevation of p21 (d'Adda di Fagagna et al, 2003; 
Stommel, 2004). Additionally, HDM2 can be inactivated by the cell cycle inhibitor 
p19
ARF
 ( Figure 8) (Zhang et al, 1998). The DDR signaling network is vastly more 
complex than outlined above. For example, ATR and ATM can also directly 
phosphorylate p53 as well as other target proteins and induce their activity (Campisi & 
d'Adda di Fagagna, 2007). The p53-p21 pathway has been well established as a primary 
senescence pathway, and depletion of DDR components (ATM or Chk2), p53, or p21 
blocks DNA damage-induced senescence (Beausejour et al, 2003; Brown et al, 1997; 
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d'Adda di Fagagna et al, 2003; Gire et al, 2004; Soule & McGrath, 1986; Won et al, 
2006). 
In many cells, severe DNA damage will also induces p16
INK4a
, another CDK 
inhibitor, secondarily to the p53-p21 pathway, providing a second barrier to prevent the 
growth of cells (Figure 8). Induction of p16
INK4a
 eventually leads to inhibition of pRb and 
cell cycle arrest (Beausejour et al, 2003; Ben-Porath & Weinberg, 2005; Jacobs & de 
Lange, 2005). This pathway was reported to be required for SAHF formation, which is 
responsible for silencing genes required for proliferation (Narita et al, 2003). 
Interestingly, once cell cycle arrest and SAHF have been formed, p16 is no longer needed 
for cell cycle arrest, and results in self maintaining senescence.   
If DNA repair is not initiated in a timely fashion, effector proteins will halt cell 
proliferation by inducing cell cycle arrest, senescence, or apoptosis. Transient cell cycle 
arrest versus terminal outcomes such as apoptosis and senescence are likely executed 
depending on the degree of damage sustained to a cell. However, how apoptosis or 
senescence is selected over each other remains unclear.  
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Figure 7. The DNA Damage Response.  
DNA damage, such as double stranded breaks, can be identified by multiple sensor 
complexes (MRN, RPA, or RPC), which trigger the DNA damage response. This results 
in recruitment of multiple kinases and adaptors, and culminates in activation of p53 and 
other effectors. Adapted from (Campisi & d'Adda di Fagagna, 2007). 
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Figure 8. Senescence is controlled by the p53 and p16 pathways. 
 
Senescence signals, including those that trigger a DNA-damage response, engage either 
the p53 and/or p16 tumor suppressor pathways. P53 is regulated by the E3 ubiquitin 
ligase, HDM2, which mediates its degradation. HDM2 itself is negatively regulated by 
ARF. Growth arrest by p53 is established in part by expression of p21, a CDK inhibitor, 
which suppresses the phosphorylation and inactivation of pRb. pRb stops proliferation by 
suppressing E2F, a transcription factor required for cell-cycle progression. E2F can also 
halt proliferation by inducing ARF expression which feeds back to p53 activation. It is 
still unclear how p16 becomes up-regulated, but it is not part of the immediate DDR. 
Adapted from(Campisi & d'Adda di Fagagna, 2007). 
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D. Oncogene Induced Senescence 
 
The DDR also plays a critical role in oncogene induced senescence. Oncogenes 
are mutants of normal genes that promote cell division and are potent inducers of 
malignant transformation. Previously, oncogenes were believed to be highly tumorigenic 
because they activated mitogenic pathways and could be found in many human tumor 
specimens or cancer cell lines (Braig & Schmitt, 2006a; Hanahan & Weinberg, 2011; 
Mooi & Peeper, 2006). However, it has become clear that aberrant mitogenic signals 
generated by oncogenes primarily result in cellular senescence, termed oncogene-induced 
senescence (OIS) (Braig & Schmitt, 2006b; Mooi & Peeper, 2006). OIS generates DNA 
damage as a result of misfired replication origins and replication fork collapse, which 
culminates in double strand breaks and activation of the DDR (Bartkova et al, 2006; Di 
Micco et al, 2007; Mallette et al, 2007). 
OIS was first observed in human fibroblasts in response to overexpression of H-
Ras
G12V
 (a cytoplasmic mitogenic signal transducer) (Serrano et al, 1997). Subsequently, 
other members of the RAS signaling pathway (RAF, MEK, and BRAF) were also shown to 
cause senescence when overexpressed or expressed as oncogenic versions in cell lines 
(Lin et al, 1998; Michaloglou et al, 2005; Zhu et al, 1998). In all cases, exclusion of p16 
or p53 abolished senescence and allowed tumor progression.(Collado & Serrano, 2010; 
Dimri et al, 2000; Lin et al, 1998; Michaloglou et al, 2005; Zhu et al, 1998).  
 Several studies in 2005 marked the first characterization of OIS in mouse models. 
Serrano et al. used a K-Ras
V12
 lung cancer mouse model which was previously 
demonstrated to develop lung adenomas and occasional lung adenocarcinomas. 
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Expression of senescence markers was found in the premalignant adenomas but not in the 
malignant adenocarcinomas. Similar results were observed in the K-Ras
V12
 pancreatic 
cancer mouse model in that the premalignant pancreatic lesions displayed evidence of 
senescence, while the ensuing pancreatic adenocarcinomas did not (Collado et al, 2005a). 
Several other groups have reported that mitogenic signaling from the Ras-Raf-Mek 
pathway promotes OIS including lung adenomas, bladder cancer, and mammary gland 
tumorigenesis (Dankort et al, 2007; Mo et al, 2007; Swarbrick et al, 2008). Michaloglou 
et al was the first to describe OIS during human cancer initiation in human melanocytic 
nevi, where these lesions exhibited evidence of senescence makers such as SA-beta-gal 
and elevated p16
INK4a
.  
OIS as a mechanism that prevents cellular transformation by excessive mitogenic 
signaling is reinforced by the fact that Ras transformed mouse fibroblasts with weak 
mitogenic signaling (i.e., cultured in serum-free medium) avoid senescence (Mathon et 
al, 2001; Tang et al, 2001; Woo et al, 2004). However, high levels of mitogenic signaling 
triggers senescence in a p53-p21 and p16-pRb dependent manner, both in vitro and in 
vivo. Using a titratable doxycycline dependent mouse model of Ras-driven mammary 
cancer, Sarkisian et al demonstrated that high levels of oncogenic H-Ras
G12V
 triggers 
senescence, but chronic low level expression of H-Ras
G12V
 promotes cell proliferation 
that eventually evolved into tumors (Sarkisian et al, 2007). In summary, these studies 
suggested that OIS is oncogene-dose-dependent. High levels of oncogenic stimuli trigger 
cellular senescence, but normal or low levels of oncogene signaling promote cell 
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proliferation, without inducing senescence, and resulting in hyperplasia after prolonged 
latency.  
Aside from the DNA damage caused robust mitotic signaling, oxidative stress 
may also play a role in OIS. Treatment of cells with H2O2 can trigger senescence in 
human fibroblasts, suggesting that reactive oxygen species (ROS) may also be a driver of 
senescence (Chen & Ames, 1994). Coupled with observation that cells transformed with 
Ras accumulate ROS (Lee et al, 1999), this suggests that oxidative stress can play a role 
in OIS. For example, Ras-induced senescence can be abrogated by treating Ras-
expressing cells with a ROS scavenger such as N-acetylcysteine. Recently, using an H-
RAS
G12V 
fibroblast model, Moiseeva et al. demonstrated a p53-dependent and pRb-
dependent increase in ROS production by dysfunctional mitochondria, prior to -mediated 
cell cycle arrest and senescence. The exact mechanism by which ROS provokes OIS 
remains unknown. One potential explanation is that that ROS causes the accumulation of 
DNA damage, thereby provoking the DDR (Guo et al, 2010). There also is some 
evidence that elevated ROS levels can activate p38MAPK and ATM signaling, which in 
turn can elicit p53 function (Lu & Finkel, 2008; Passos et al, 2010).  
Finally, there have been multiple studies using human tissue samples that suggest 
that OIS is a barrier to tumorigenesis beyond the initial study of BRAF nevi. For 
example, in a study of colonic adenomas and precancerous bladder lesions, features of 
senescence were found, but not in the malignant counterparts (Bartkova et al, 2006). 
Other groups confirmed the presence of senescent cells in colon adenomas but not colon 
carcinomas. Additionally, another group showed that dermal neurofibromas from patients 
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with the familial cancer syndrome neurofibromatosis type 1 (NF1), also have markers of 
senescence. Here, mutations in the NF1 gene results in increased Ras signaling which 
may explain this observation (Courtois-Cox et al, 2006).  
The circumvention of OIS may be a prerequisite in the stepwise transition from a 
premalignant lesion to an advanced tumor (Figure 9). Malignant transformation is a 
multistep process. Previously, it was thought that restored telomerase activity, together 
with activation of oncogenes, were the prerequisite for malignant transformation (Bodnar 
et al, 1998; Hahn et al, 1999; Kiyono et al, 1998).  However, it was shown in 2002 that it 
is sufficient to combine two oncogenes with p53 inhibition in order to transform human 
cells in vitro and form tumors in vivo (Seger et al, 2002). This notion has been confirmed 
by experiments in which p53 knockout animals developed various tumors upon challenge 
with carcinogens or oncogene activation (Hanahan & Weinberg, 2011). The p53-
dependent senescence pathway provides a primary defense system against cancer 
development by preventing the proliferation of cells with severe DNA damages that 
could be at risk for oncogenic mutations. Therefore, cells need to acquire mechanisms to 
suppress OIS pathways, and the may partially explain why the mediators of OIS are 
frequently mutated in human cancers. For example, 50% of human cancers bear disabled 
p53 either by mutations or by overexpressing Twist and Snail to effectively suppress p53 
transcription (Ansieau et al, 2008). Other types of cancers with an intact, functional p53 
pathway require alternate ways to bypass OIS. Collectively, these reports extend into the 
clinical setting the observations that OIS represents a prominent barrier to tumor 
progression that must be bypassed for malignant progression.   
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Figure 9. Oncogene Induced Senescence: A Barrier to Malignant Transformation. 
Oncogene activation resulting in strong mitogenic signaling triggers either apoptosis or 
senescence depending on the oncogene and tissue type. In order to progress to malignant 
tumorigenesis, cells must also circumvent senescence programing via inactivation or 
mutation of mediators of senescence pathways such as p53 or p16.  
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E. Senescence and Cancer Treatments 
 
Reactivation of tumor suppressor networks as a means to re-induce OIS may 
represent a novel therapeutic strategy in advanced tumors. For example, certain cancer 
cell lines undergo senescence upon chemotherapy, indicating that while malignant cells 
may have bypassed senescence, they have not lost their senescence capability (Chang et 
al, 1999a; Chang et al, 2002; Chang et al, 1999b; Shay & Roninson, 2004a). In this case, 
senescence is expected to have tumor regression effect in vivo. For example, in mouse 
models utilizing an on/off p53 switch, different tumors were generated (lymphoma, 
sarcomas, or carcinomas) while the p53 pathway was turned off. Following re-activation 
of p53, massive apoptosis was observed in lymphoma regression, but a large extent of 
senescence was detected in the sarcoma and carcinoma models (Martins et al, 2006; 
Ventura et al, 2007; Xue et al, 2007). Interestingly, restoration of p53 only triggered 
senescence or apoptosis in tumor cells without affecting normal tissues, possibly due to 
high levels of mitotic signaling in the tumor cells.  
The most widely used treatments for cancer are chemotherapies and irradiation. 
The rationale behind their effectiveness is that they case extensive DNA damage in 
rapidly dividing cells, thus they predominantly target the quickly dividing cancer cells. 
This DNA damage response can induce apoptosis, but they can also trigger senescence. 
Chang et al found senescence-like morphological changes and SA-beta-gal expression in 
fibrosarcoma cell lines after treatment with a variety of anti-cancer agents. Similarly, 
senescence was found in cisplatin treated solid tumor cell lines (Wang et al, 1998) and in 
hydroxyurea-treated K562 leukemia cells (Park et al, 2000). Some observations in 
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radiation therapy suggest that senescence could be the primary mode of treatment 
response in certain clinical cases. In particular, complete regression of prostate cancers 
took more than a year in some patients after radiation treatment, and regression of 
desmoid tumors took up to two years (Bataini et al, 1988; Cox & Kline, 1983). This slow 
course of tumor dissipation seems most consistent with radiation-induced senescence. Te 
Poele et al was the first to demonstrate a senescent phenotype in frozen archival breast 
tumors of patients who had received neoadjuvant chemotherapy (CAF regimen: 
cyclophosphamide, doxorubicin, and 5-fluorouracil), including increased SA-β-gal 
activity and high staining of p16
INK4a 
(te Poele et al, 2002).  Activating the program of 
senescence in tumor cells seems an attractive approach to cancer treatment. However, 
senescence has also been suggested be a “double-edged sword” (Kim et al, 2007; 
Vichalkovski et al, 2010). On one hand, OIS prevents cancer pathogenesis by acting as a 
tumor suppressor. On the other hand, senescent cells secrete a variety of factors which 
may actually support tumor growth.  
F. Senescence Associated Secretory Phenotype and Cancer Therapy 
 
As previously mentioned, senescent cells secrete a broad spectrum of factors, 
including growth factors, extracellular matrix modifying proteins, cytokines, and 
chemokines, termed the senescence associated secretory phenotype (SASP) (Rodier & 
Campisi, 2011). These factors can have myriad effects on the cellular microenvironment, 
and play a large role in the paradoxical nature of senescence. Some factors function to 
reinforce the senescence phenotype and tumor suppression, while others have been 
shown to promote tumor progression.  
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In terms of encouraging senescence, several groups have employed genetic 
approaches to isolate discrete secreted factors critical to OIS. For example, shRNA-
mediated knockdown of insulin-like growth factor-binding protein 7 (IGFBP7) bypassed 
mutant BRAF
V600E
 mediated senescence in cultured fibroblasts. IGFBP7 was also shown 
to be down-regulated in malignant melanomas expressing BRAF
V600E
 (Wajapeyee et al, 
2008), presumably creating a permissive environment for malignant progression. Another 
group found that the chemokine IL-6 was up-regulated in BRAF
V600E
 overexpressing 
cells, and down-regulation of this factor or its receptor allowed bypass of BRAF-
mediated OIS (Kuilman et al, 2008).  Additionally, the chemokine receptor 2 (CXCR2) 
was required for OIS in human fibroblasts, and overexpression of CXCR2 or its ligands 
IL-8 or GROa/Gro-1 triggered senescence in these cells (Acosta et al, 2008). These 
findings imply that secreted factors also play a major role in OIS and may synergize with 
aforementioned mechanisms (DDR, SAHF formation, ROS, and tumor suppressor gene 
inductions) in order to induce and maintain OIS.  For example, Rodier et al found that 
components of DDR signaling were required for the secretion of cytokines (IL-6 and IL-
8) in senescent fibroblasts after exposure to high dose ionizing radiation (IR), thus 
illustrating the intertwined nature of the DDR and SASP in driving OIS (Rodier et al, 
2011).  
Aside from reaffirming senescence, the SASP may also play a role in invoking 
innate immunity to clear tumors. In the p53 on/off switch model of liver carcinoma, Xue 
et al demonstrated that senescence-associated tumor regression was accompanied by the 
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infiltrating macrophages, NK cells and neutrophils, which was dependent on secretion of 
IL-6 and IL-8 (Xue et al, 2007). Secreted factors were also determined to initiate an 
adaptive immune surveillance of premalignant senescent cells in another model of liver 
cancer (Kang et al, 2011). 
However, some reports have shown that senescent cells or the conditioned media 
derived from their culture, can exhibit mitogenic effects. For instance, senescent 
fibroblasts have been demonstrated to enhance the growth of various premalignant cell 
types, including mammary epithelial cells (Krtolica & Campisi, 2002). Additionally, 
SASP factors can boost cancer progression by promoting proliferation, triggering 
epithelial-mesenchymal transition (EMT), and stimulating angiogenesis (Chang et al, 
2002; Coppé et al, 2006; Krtolica et al, 2001; Parrinello et al, 2005).  Many of these 
tumor-promoting secreted proteins were linked to p21. For example, knockout of p21 in 
replicatively senescent HT1080 fibrosarcoma cells decreased or delayed induction of the 
epithelin (mitogenic), prosaposin (anti-apoptotic), and PAI-1 (angiogenic) (Chang et al, 
2000).  
In support of senescence inducing therapies, due to the SASP, if not all of the 
tumor cells are rendered senescent as a result of treatment, such cells may provide a 
reservoir of secreted tumor-suppressing factors that will inhibit the growth of non-
senescent cells. On the other hand, because senescent cells can overexpress secreted 
tumor-promoting factors, senescence may have potential adversarial effects in the short 
term (growth stimulation of non-senescent tumor cells) and long term (increased 
likelihood of de novo carcinogenesis) (Figure 10). 
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Figure 10. Possible Outcomes of Cancer Therapy and Senescence Induction. 
While many therapies strive to induce apoptosis as their main mechanism of tumor 
regression, the same mechanism may instead activate senescence pathways. Induction of 
senescence after cancer therapy and its overall effect in the long term has yet to be fully 
understood. Based on the current research, especially with regard to recent work in the 
senescence associate secretory phenotype (SASP) and its paracrine effect on neighboring 
cells, there are four potential outcomes of triggering senescence in patients. Some aspects 
of the SASP reinforce senescence and may result in terminal cancer cell growth arrest. 
Other factors may attract immune cells and activate tumor clearance in this manner. 
Detrimentally, many of the factors secreted by senescent cells can promote tumor cell 
proliferation and may cause a future relapse if not cleared. Additionally, some of the 
cancer cells may not be able to activate the DNA damage pathways and so will be 
refractory to senescence-inducing treatment with continued proliferation and may have 
accrued additional mutations from DNA damage therapy.  Adapted from (Kahlem et al, 
2004) 
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3. HSP70 and Human Cancers 
A. Overview 
 
HSPs are elevated in many different cancer types. Their overexpression tends to 
correlate with poorer prognoses in therapy response and overall patient survival, 
suggesting that HSPs play a critical role in cancer (Ciocca & Calderwood, 2005). The 
fact that high levels of HSPs suppress stress-induced apoptosis and senescence is 
believed to provide selective advantage for cancer cell survival and promotes tumor 
progression.  
B. HSP70 Correlation in Human Cancers 
 
HSP70 is overexpressed in a wide variety of human cancers (see Table 3). It has 
been suggested to be a biomarker for some cancers (Abe et al, 2004; Di Tommaso et al, 
2009; Elstrand et al, 2009; Seoane et al, 2006; Shin et al, 2011; Syrigos et al, 2003). For 
others, the expression level of HSP70 correlates with tumor size, clinical stage, and 
lymph node metastasis (Hwang et al, 2003; Kaur et al, 1998; Lazaris et al, 1995; Ralhan 
& Kaur, 1995).  HSP70 has also emerged as a predictor for therapy resistance (Liu & 
Hill, 1996; Pocaly et al, 2007; Ren et al, 2008; Sliutz et al, 1996; Vargas-Roig et al, 1998; 
Yiu et al, 2010). In line with these observations, high expression of HSP70 has been 
linked to poorer patient survival rates (Kocsis et al, 2011; Rozenberg et al, 2013; Shin et 
al, 2011; Thomas et al, 2005; Vargas-Roig et al, 1998; Yeh et al, 2010; Yeh et al, 2009) . 
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Table 4. Summary of HSP70 in Cancer 
Cancer Type Correlation with Hsp70 Reference
AML Poor prognosis
Yeh et al, 2010                       
Thomas et al, 2005
Bladder Biomarker Syrigos et al, 2003
Breast
Advanced disease;              
Lymph node metastasis;            
Radiation resistance;        
Clinical Stage;                  
Poor prognosis
Yiu et al, 2010                    
Liu et al, 1996          
Vargas-Rois et al, 1998         
Kalogeraki et al, 2007                    
Asfour et al, 2011
Cervical/Uterine
Poor prognosis;              
Tumor Size
Ralhan et al, 1995
CML Imatinib resistance
Pocaly et al, 2007              
Yeh et al, 2009
Colorectal
Advanced disease;                 
Lymph node metastasis;      
Poor prognosis          
Hwang et al, 2003 
Rozenberg et al, 2013 
Kocsis et al, 2011
Fibrosarcoma
Topotecan resistance      
Gemcitabine resistance
Sliutz et al, 1996
Hepatocellular
Biomarker for early disease; 
Clinical stage;                      
Poorer prognosis 
Di Tommaso et al, 2009   
Shin et al, 2011
Melanoma Increases with clincial stage Lazaris et al, 1995
Ovarian
Biomarker for 
undifferentiated disease
Elstrand et al, 2009
Oral/Head/Neck
Biomarker for early disease; 
Increases with clinical stage
Seoane et al, 2006       
Kaur et al, 1998
Prostate
Biomarker for early disease; 
Cisplatin resistance
Abe et al, 2004 
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C. HSP70 and Cancer Related Pathways 
 
In 2007, the Lindquist and Mivechi groups discovered that Hsf1 knockout 
prevents development of certain types of cancer in mice (Dai et al, 2007; Min et al, 
2007). For example, knock out of HSF1 delayed tumor growth in response to chemical 
carcinogens and increased overall animal survival. Additionally, HSF1 knock out 
deferred lymphoma development in p53-deficient mice and also delayed carcinogenesis 
in p53 knock-in mutant (R172H) mice. More recently several publications reported that 
Hsf1 is critical for development of a variety of cancer at several stages (Dudeja et al, 
2011; Gabai et al, 2012; Meng et al, 2010; Xi et al, 2012). Previously, using Her2 
transformed MCF10A cells, we determined that the major effect of HSF1 on tumor 
development is via up-regulation of HSP70, and knockout of HSP70, is enough to 
similarly block cancer development in the model of Her2-postive breast cancer (Meng et 
al, 2010; Meng et al, 2011). Overall, Hsf1 and HSP70 are critical for the survival and 
growth of many types of cancer cells, but are dispensable for normal cells.  
Following discovery of the essential role of Hsf1 in tumor development, a novel 
paradigm emerged called “non-oncogene-addiction”. According to this idea, cancer cells 
acquire properties that make their survival dependent on proteins which are expendable 
for a normal cell (Luo et al, 2009). The natural evolution of this idea lends the hypothesis 
that tumor cells have increased demand for molecular chaperones due to elevated levels 
of abnormal proteins, which accumulate as a result of the toxic conditions associated with 
the tumor microenvironment (hypoxia, nutrient deprivation, etc.) (Luo et al, 2009; 
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Mosser & Morimoto, 2004). However, this argument would not be valid in standard 
conditions of cell culture, yet dependence on chaperones persists.  
On the other hand, cancer cells are usually aneuploid, and as such have an 
imbalance in protein complexes, a characteristic which by itself may demand high levels 
of chaperones (Mosser, 2004; Torres et al, 2007). This mechanism was proposed to 
explain why cancer cells become “addicted” to increased activity of Hsf1, HSP70, and 
other chaperones (Solimini et al, 2007). This hypothesis is widely accepted in the field 
and is supported by certain evidence. For example, aneuploid strains of yeast are 
sensitive to conditions that interfere with protein translation, folding and degradation 
(Pavelka et al, 2010; Torres et al, 2010; Torres et al, 2007). Also, mammalian cell strains 
that have certain extra chromosomes demonstrate increased sensitivity to inhibitors of the 
chaperone HSP90 (Tang et al, 2011). This data, however, is circuitous, and a direct test of 
the model has not been carried out. Understanding why cancer cells become “addicted” to 
HSP70 is of fundamental importance for therapy development.  
 Estrogen Signaling i.
 
As mentioned above, HSP70 has been shown to have significant clinical 
correlation with breast cancer. Important to many subtypes of breast cancer is steroid 
receptor signaling. HSP70 was reported to assist in the assembly and trafficking of 
steroid receptors, and in breast cancer, HSP70 has been associated with the estrogen 
receptor-α (ERα) (Sai Padma et al, 2000; Takahashi et al, 1994). Using MCF7 cells, 
HSP70 has been shown to increase ERα transcriptional activity and cell growth, which 
may explain the increased cell proliferation found in ER positive breast tumor biopsy 
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samples that express HSP70 (Hurd et al, 2000; Vargas-Roig et al, 1998). Interestingly, 
although HSP70 expression is associated with ER activity in breast cancer, there was no 
predictive value for HSP70 expression in relation to treatment with tamoxifen, an 
estrogen receptor antagonist (Ciocca et al, 1998) . 
 Apoptosis ii.
 
There have been a series of publications that addressed a possible mechanism that 
defines the specific requirement for HSP70 of cancer cells. Originally, the major focus 
was on the anti-apoptotic function of HSP70. HSP70 acts at multiple points of the 
apoptotic pathways to ensure that stress-induced damage does not inappropriately trigger 
cell death (Murphy, 2013; Schmitt et al, 2007).  
There are two main apoptotic pathways, the extrinsic and intrinsic apoptotic 
pathways. Both signaling pathways result in the activation of effector caspases, cysteine 
proteases which are the primary drivers of apoptosis. The extrinsic pathway is triggered 
through the TNF receptor family known as death receptors (DRs), and leads to the direct 
activation of caspases, especially caspase-8. The intrinsic pathway integrates intracellular 
stress signals that results in the production or activation of pro-apoptotic molecules, such 
as BID or BAX, which converge on the mitochondria. These pro-apoptotic molecules 
cause permeabilization of the mitochondrial membrane and result in the release of 
cytochrome c from the inner mitochondrial membrane. In the cytosol, cytochrome c 
interacts with cytosolic apoptosis protease-activating factor-1 (Apaf-1) and pro-caspase-9 
to form the apoptosome, which is the caspase-3 activation complex. Another factor from 
51 
 
 
the mitochondria, apoptosis initiating factor, AIF translocates to the nucleus and triggers 
caspase-independent nuclear changes (for review see (Lowe & Lin, 2000)).  
Adaptations that prevent apoptosis are one of the major hallmarks of cancer cells 
since they experience a variety of stressful conditions on their pathway towards tumor 
development, including escape of apoptosis caused by some oncogenes (e.g. myc), 
anoikis, harsh conditions of tumor microenvironment, and others (Hanahan & Weinberg, 
2011; Jamerson et al, 2004; Juin et al, 1999; Kim et al, 2012b; Liao & Dickson, 2000; 
Nilsson & Cleveland, 2003). In line with these problems encountered by cancer cells, 
HSP70 has strong anti-apoptotic activity. Elevated HSP70 levels block the apoptotic 
pathways at multiple points in the pathways. HSP70 has been shown to bind to the death 
receptors, DR4 and DR5, thereby inhibiting the TNF receptor apoptosis inducing ligand 
(TRAIL)-induced apoptosis (Guo et al, 2005). Additionally, HSP70 inhibits activation of 
the stress activated kinase, c-Jun N-terminal Kinase (JNK), and the Bid-dependent 
apoptotic pathway downstream of TNF signaling (Gabai et al, 2002). HSP70 also blocks 
multiple steps in the intrinsic apoptotic pathway. For example, HSP70 has also been 
reported to bind and sequester Apaf-1 and AIF, preventing apoptosome formation and 
AIF-induced chromatin condensation, respectively (Beere et al, 2000b; Ruchalski et al, 
2006).  
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 Senescence iii.
 
While HSP70 depletion causes apoptosis in certain circumstances, alternatively it 
may cause senescence, especially in cells of epithelial origin. Previous work in our 
laboratory showed that knockdown of HSP70 inhibits cell proliferation and triggers 
senescence in a variety of cancer lines, but not in untransformed epithelial cells. For 
example, depletion of either HSP70 or Hsf1 in untransformed breast epithelial line 
MCF10A is not harmful (Gabai et al, 2009; Meng et al, 2010; Meng et al, 2011). 
However, similar depletion in cells transformed with Her2 or PIK3CA oncogenes leads 
to growth arrest and overall senescence (Gabai et al, 2009; Meng et al, 2010). Depending 
on which oncogene was present, PIK3CA or Ras, depletion of HSP70 triggered either a 
p53- or a MAPK-dependent senescence signaling pathway, respectively (Gabai et al, 
2009).  
We also assessed the role of HSP70 in cancer development using a HER2/NeuT 
model. Her2/NeuT overexpression led to MCF10A mammary epithelial cell 
transformation, and injection of these cells into nude mice resulted in rapid tumor 
development. However, in HSP70 depleted MCF10A cells, Her2/NeuT expression did 
not result in transformation, but rather senescence, and these cells failed to form tumors 
in mice. Furthermore, knock out of HSP70 in the MMTVneu mouse model drastically 
reduced tumor emergence, and examination of the HSP70-/- MMTVneu mammary 
glands found widespread ductal epithelial cell senescence (Meng et al, 2011). These 
studies indicated that HSP70 controls OIS and is important for tumor initiation. However, 
because of senescence, this model did not allow us to clarify a mechanism, nor did it 
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address what other roles HSP70 might play in tumor progression, both of which are 
necessary in order to determine the best way to target HSP70 for cancer therapy. 
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4. Targeting HSP70 for Cancer Therapy 
A. Overview 
 
While HSP70 has been demonstrated to be critical for cancer cells, it is 
dispensable for viability and growth of non-transformed cells.  Normal cells usually 
express low levels of HSP70 in the absence of stress. However, HSP70 is constitutively 
elevated in many tumors and cancer cell lines (Ciocca & Calderwood, 2005). The 
requirement of HSP70 overexpression for neoplastic growth and viability, the 
dispensability of HSP70 in non-transformed cells and animal models, and the success of 
other HSP inhibitors, suggests a therapeutic potential for small molecule inhibitors of 
HSP70 (Gabai et al, 2009; Meng et al, 2011; Powers et al, 2008; Powers et al, 2010).  
B. General Heat Shock Protein Inhibitors 
 
The first approach to inhibit HSP70 was through abrogation of HSP70 expression 
via inhibition of its major transcriptional driver, HSF1. Quircetin (a bioflavonoid) was the 
first compound to inhibit HSF1 activity and demonstrated inhibition of HSP70 mRNA 
expression (Hosokawa et al, 1992; Koishi et al, 1992). A more potent HSF1 inhibitor, a 
benzylidene lactam compound- KNK437, was suggested as an effective sensitizer for 
cancer hyperthermic therapy and as a potentiating agent for use in conjunction with an 
HSP90 in myelomas (Davenport et al, 2010; Sahin et al, 2011; Yokota et al, 2000).  (Xia 
et al, 2012) reported a triazole nucleoside analog inhibitor of HSF1 that elicits potent 
anticancer activity on drug-resistant pancreatic cancer. Using a high throughput screen, 
our lab also identified a dehydroemetine derivative, NZ28 and emunin, which regulates 
55 
 
 
HSP translation rather than HSF1 activation, and sensitized myeloma cells to proteasome 
and HSP90 inhibitors and prostate carcinoma cells to proteasome inhibitors (Zaarur et al, 
2006). However, all of these approaches are non-specific for HSP70. Current 
classification divides HSP70 inhibitors into three groups based on their target: the 
substrate binding domain (SBD), the nucleotide binding domain (NBD), and targeting 
HSP70 co-chaperone binding. 
 
C.  HSP70 Substrate Binding Domain Inhibitors 
 
PES (2-phenylethynesulfonamid), also known as pifithrin-μ, was originally 
identified in a cell-based compound library screen as an inhibitor of p53 mitochondrial 
pro-apoptotic activity (Strom et al, 2006). While p53 is a transcriptional regulator, it also 
is known to play a part in triggering the mitochondrial apoptosis pathway. In response to 
apoptotic stimuli, a fraction of p53 localizes to the mitochondria and destabilizes the 
interaction of the Bcl-2 anti-apoptotic family members, such as Bcl-XL, with their pro-
apoptotic counterparts (Bax and Bad), resulting in mitochondrial membrane 
permeabilization and apoptosis (Mihara et al, 2003). PES was reported to bind to the p53 
DNA-binding domain and prevented formation of the p53-Bcl-xL complex (Hagn et al, 
2010).  Alternatively, PES has been shown to interact with HSP70. In pull down 
experiments using a biotinylated form of PES, they found that PES did not associate with 
p53, but rather bound HSP70. Deletion analysis suggested that PES interacted with the 
SBD region of HSP70 and disrupts its association with its co-chaperones (including 
HSP40 and CHIP) and client proteins (Leu et al, 2009). Leu et al. concluded that the 
56 
 
 
PES-mediated inhibition of HSP70 family proteins in tumor cells resulted in protein 
aggregation related to impairment of the autophagy-lysosome system and the proteasome 
pathway. More recent reports have indicated that PES binds to the NBD of HSP70, and 
that PES can induce p53-independent mitochondrial apoptosis pathways (Leu et al, 2011; 
Steele et al, 2009).  
Another strategy for targeting the HSP70 substrate domain was to rationally 
design substrate domain decoy clients. HSP70 was previously shown to bind to AIF, and 
this characteristic was taken advantage of by the Garrido lab. ADD70 (AIF derived decoy 
for HSP70) is a peptide inhibitor of HSP70. All AIF-derived peptides contain the AIF 
region required for HSP70 substrate binding but do not carry AIF’s pro-apoptotic 
function (Schmitt et al, 2003).  When transfected into cells used for subcutaneous 
xenografts, ADD70 decreased the size of the tumors in a rat colon cancer cell model and 
induced growth delay B16 melanomas in mice. Using these same models, ADD70 also 
sensitized both the rat colon cancer cells and mouse melanoma cells to cisplatin (Schmitt 
et al, 2006). More recently, an array of synthetic peptide aptamer derivatives containing 8 
to 13 amino acids, were screened for their ability to bind to HSP70 and specifically 
inhibit HSP70 chaperone activity, but not the chaperone activity of HSC70 or HSP90. 
Like ADD70, these smaller aptamers also showed chemo-sensitizing effects to cisplatin 
in vitro and tumor regression in vivo (Rerole et al, 2011). However, in vivo, the effect of 
ADD70 and the smaller aptamers appeared to be related to their ability to increase tumor-
infiltrating cytotoxic CD8+ T-cells and not necessarily for inhibiting the chaperone 
capability of HSP70 itself (Rerole et al, 2011; Schmitt et al, 2007; Schmitt et al, 2003). 
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Additionally, it is unclear how selective these aptamers for cancer cells and the use of 
aptamers is limited due to the delivery problems. 
 
D. HSP70 Nucleotide Binding Domain Inhibitors 
 
The HSP70 chaperone cycle is dependent on ATP hydrolysis and ADP/ATP 
exchange, therefore disruption of HSP70-ATP interaction could lead to the inability of 
HSP70 to perform its functions. 15-deoxyspergualin (15-DSG) was the first natural 
product shown to bind to bovine HSC70 and stimulate its ATPase activity.(Brodsky, 
1999; Nadeau et al, 1994) In a screen for other inhibitors of the HSP70 ATPase, NSC 
630668, which is structurally related to 15-DSG and belongs to the dihydropyrimidines, 
was identified using the Developmental Therapeutics Program database at the National 
Cancer Institute. NSC 630668 was tested on yeast and was shown to inhibit HSC70 
ATPase activity and blocked HSC70 mediated protein translocation (Fewell et al, 2001). 
A second generation compound, MAL3-101 and subsequent derivative, also obstructs 
HSP70 ATPase activity and blocked proliferation of a breast cancer cell line (Huryn et al, 
2011). Derivatives of MAL3-101 modulate HSP70, but exhibit divergent 
pharmacological activities. For example, MAL2-11B suppressed J domain-enhanced 
HSP70 ATPase activity, but a structural analog stimulated ATPase activity (Huryn et al, 
2011). The exact site and mode of binding of these molecules are currently unknown.  
 
VER-155008 is an adenosine-derived compound that fits into the ATPase domain 
of HSP70 (Williamson et al, 2009). It was shown to induce caspase dependent apoptosis 
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in BT474 breast cancer cells and non-caspase dependent death in HCT116 colon cancer 
cells (Massey et al, 2010). However, VER-155008 was also found to be a nonselective 
pan-inhibitor of the entire HSP70 family. Macias et al. able to find a specific ATPase 
inhibitor of GRP78 (the ER associated HSP70 family member), attesting to the 
possibility of designing specific inhibitors to the different HSP70 members (Macias et al, 
2011). However, these compounds in vivo were rapidly metabolized and cleared, and the 
estimated tumor accumulation was below the predicted pharmacologic dose (Massey et 
al, 2010).  
MKT-077 was shown to bind to a negatively charged pocket in the NBD separate 
from the ATP binding site in HSP70 proteins. The binding of MKT-077 to the HSP70 
NBD occurs preferentially when in the ADP allosteric state, making MKT-077 an 
“allosteric drug” (Rousaki et al, 2011). MKT-077 went so far as to enter phase 1 clinical 
trials for treatment of solid tumors, but was abandoned due to renal toxicity, which was 
later attributed to its accumulation in mitochondria (Britten et al, 2000; Propper et al, 
1999). Later, MKT-077 was found to interact with mortalin. Mortalin is the 
mitochondrial version of HSP70, but there is a pool of mortalin that can be found in the 
perinuclear cytosol. This cytoplasmic mortalin has been shown to sequester p53 and 
prevent its pro-apoptotic effects as mentioned previously (Wadhwa et al, 1999).  The 
interaction of MKT-077 with mortalin was found to release p53 from this inhibitory 
complex and induce cell death (Wadhwa et al, 2000).  
The identification of the MKT-077 binding pocket and the orientation of the drug 
within the pocket has allowed for the design of more potent, selective, and importantly, 
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less toxic MKT-077 derivatives (Rousaki et al, 2011). One of these derivatives, YM-1 
has been shown to have enhanced cytotoxic effects across multiple cancer cell lines due 
to an improved cytosolic localization over the original MKT-077 compound (Koren et al, 
2012) and shows promise for future drug development. 
Most recently, a new allosterically-binding compound, YK5, was described. Like 
MKT-077 and its YM-1 derivatives, YK5 also binds to a pocket distinct from the 
nucleotide binding pocket (and also different from the MKT-077 pocket).  YK5 inhibited 
the refolding capability of HSP70 and inhibited the HSP70/HSP90 complex formation 
and resulted in degradation of HSP90 clients such as Her2, Akt, and Raf-1 (Rodina et al, 
2013). However, it has not been tested in vivo. 
 
E. Targeting HSP70 Co-chaperones 
 
Another way of impairing HSP70 activity is by inhibiting the activity of its co-
chaperones. Different combinations of HSP70 co-chaperone interactions could lead to 
distinct effect on cell homeostasis and survival. For example, targeting bacterial HSP70 
co-chaperone DnaJ (homolog to human HSP40) with a D-peptide inhibits chaperone-
dependent protein refolding and DnaJ stimulated ATPase activity of HSP70 
(Bischofberger et al, 2003). Alternatively, MAL2-11B, an intermediate of MAL3-101 
synthesis, was also shown to inhibit the ability of HSP40 to stimulate HSP70 ATPase 
activity but requires further testing (Huryn et al, 2011). 
In order to tailor inhibitor development to cancer specificity, we have focused on 
defining mechanisms underlying the effects of HSP70 on tumor development and 
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identified the interaction of HSP70 with the co-chaperone, BAG3, to be critical for 
cancer related signaling pathways.  Using the MKT-077 derivative, YM-1, we show that 
it is possible to specifically inhibit the HSP70-BAG3 signaling axis, leading to selective 
inhibition of growth of cancer cells and inhibition of tumor growth in vivo.  
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Chapter II.  Materials and Methods 
1. Reagents 
Bio-Rad Protein Assay Reagent Bio Rad  
Bovine Serum Albumin Chem Cruz- Santa Cruz Biotechnology 
Cholera Toxin 1.0mg/mL stock in dH2O; Sigma. 
Complete Protease Inhibitor Tablets  Roche   
DNA Midi Kit Qiagen 
DTT 1M stock; Sigma 
Dulbecco’s Modified Eagle Medium  Cellgro  
Dulbecco’s Modified Eagle’s Medium- 
Ham’s F12 50:50 Mix Cellgro  
Dulbecco’s Phosphate Buffered Solution Cellgro 
ECL Reagent ThermoSientific  
EDTA 0.5M stock; American Bioanalytical 
EGTA 0.5M stock: American Bioanalytical 
Epidermal growth factor 20ug/mL stock solution in PBS; Invitrogen  
Fetal Bovine Serum Atlas 
Glutathione Sepharose Beads GE Healthcare  
HEPES 1M stock solution; Boston Bioproducts  
Horse Serum Gibco 
Hydrocortisone 2mg/mL stock solution in isopropanol; 
Sigma 
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Hydrogen Peroxide Sigma 
Insulin 10mg/mL stock solution in HCl pH2; Sigma  
JG-36 10mM Stock in DMSO;  
 Gift from Gestwicki Lab 
JG-84 10mM Stock in DMSO;  
 Gift from Gestwicki Lab 
JG-98 10mM Stock in DMSO;  
 Gift from Gestwicki Lab 
Lipofectamine 2000 Transfection Reagent Invitrogen  
Luciferase Reporter Reagents Promega 
Matrigel BD Biosciences 
McCoy’s 5a Medium Cellgro  
MG-132 5mM stock solution; Enzo 
Nitrocellulose Membranes BioRad  
Opti-MEM Medium Invitrogen 
Penicillin/Streptomycin Solution Gibco 
Phenylmethanesulfonyl fluoride Stock Solution 100mM in 100% ethanol; 
Sigma  
 
Phosphatase Inhibitor Cocktail 3  Sigma  
Precision Plus Protein Standard  BioRad 
Protein A/G Sepharose Beads Santa Cruz 
Protein G Plus Sepharose Beads Santa Cruz  
Retroscript Kit Ambion 
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RNeasy Kit Qiagen 
Sodium Fluoride 1M stock in H2O; Sigma 
Sodium Orthovanadate 0.8M stock in H2O; Sigma 
Sybr Green Master Mix Qiagen 
Triton-X 100 Sigma 
Trypsin Gibco 
YM-1 50mM Stock in DMSO;  
 Gift from Gestwicki Lab 
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2. Antibodies 
Akt      Santa Cruz 
BAG3 Gift from Takayama Lab 
β-actin Cell Signaling 
FLAG (M2) Sigma 
FLAG ((F7425) Sigma 
FoxM1 Santa Cruz 
HIF1-α BD Pharmingen 
HSP70 Stressgen 
HuR Santa Cruz 
IKK-γ Rockland 
IκBα Cell Signaling 
p130Cas Cell Signaling 
p21 BD Pharmingen 
p27 BD Pharmingen 
Goat α-Mouse HRP Linked Secondary Cell Signaling 
Mouse Trublot Rockland 
NF-κB  Cell Signaling 
p-NF-κB (S536) Cell Signaling 
p-p130Cas (Y165, Y249, Y410) Cell Signaling 
p-paxillin Cell Signaling 
p-SRC (Y416)  Cell Signaling 
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Raf-1 Santa Cruz 
Goat α-Rabbit HRP-linked Secondary Cell Signaling 
SRC (mouse) Santa Cruz 
SRC (rabbit) Cell Signaling 
Survivin Santa Cruz 
Ubiquitin (multi) Enzo 
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3. Cell cultures 
  MCF10A, HEK293, MCF-7, HeLa, and HCT116 were from ATCC. MCF10A 
cells expressing PIK3CA or Her2 were as described before (Gabai et al, 2009; Meng et 
al, 2011). MCF10A cells were cultivated in Dulbecco's modified Eagle's medium-F12 
medium supplemented with 5% horse serum, hydrocortisone (500 ng/ml), insulin (10 
μg/ml), cholera toxin (100 ng/ml), and epidermal growth factor (20 ng/ml). HEK293T 
cells were maintained in DMEM supplemented with 10% heat inactivated fetal bovine 
serum (FBS). MCF7 and HeLa cells were cultivated in Dulbecco's modified Eagle's 
medium supplemented with 10% FBS. HCT115 were grown in McCoy’s 5a Medium 
with 10% FBS. All cultures contained 1% penicillin/streptomycin. For heat shock at 
45°C, a circulating water bath was used.  
4. Plasmids, Vectors, and DNA Amplification 
Retroviral and lentiviral vectors- RNAi-Ready pSIREN-RetroQ vector from BD 
Biosciences retroviral delivery system was used for knockdown of HSP70. The sequence 
of human HSP70 gene was selected as reported before (Yaglom et al, 2007): 
5′TATGGACTCCAACCTGGATAA-3′.  
BAG3 gene silencing was accomplished using pLTRH1-shBAG3 obtained from 
Dr. Takayama. The sequences for BAG3 gene are as reported (Homma et al, 2006):  
Forward: 5’-GATCCCGTACCTGATGATCGAAGAGTTTCAAGAGAACTCTTCGAT 
CATCAGGTATTTTTGGAG-3′ 
Reverse: 5′-TCGACTTCCAAAAAATACCTGATGATCGAAGAGTTCTCTTGAAAC 
TCTTCGATCATCAGGTACGG-3′.  
67 
 
 
HSE-luc lentiviral vector as described previously (Kim et al, 2012a) using 
pGreenFire lentiviral vector (System Biosciences, Mountain View, Ca): six tandem 
repeats of heat shock elements (HSE)- 5’-
GAACCTTCGCGAATTTTCAAGAATGTTCAGGAATATTCTAGAACTTTCCTGAA
CCTT-3’at the ClaI and SpeI sites.  
NRF2-luc lentiviral vector was constructed using the pGreenFire Lentiviral vector 
(System Biosciences): six tandem repeats of the NRF2 consensus sequence- 5’-TCACAG 
TGACTCAGCAAAATT-3’ between the Cla1 and Spe1 sties. 
BAG3 deletion constructs were a gift from Dr. Takayama. Briefly, the full length 
BAG3 cDNA was cloned into pcDNA3.1 using the EcoRI and XhoI sites. The N-
terminal FLAG tag sequence was inserted using the HindIII and BamHI sites.  The 
BAG3-ΔB construct is missing nucleotides 1261-1494 from the first ATG, while the 
BAG3-ΔPxxP construct deleted nucleotides 907-1260.  
For DNA amplification, 1μg of each plasmid or vector was transformed into the XL-
Blue competent bacterial strain. Bacteria were grown in LB media with ampicillin. DNA 
was collected using Qiagen DNA Miniprep or Midiprep kits. DNA concentration was 
determined using UV/Vis 260/280 ratio.  
5. Transfections and Virus Production 
For transfections, construct DNA was mixed with Lipofectamine 2000 in Opti-
MEM and added directly to cell media. GFP was used as a control for transfections. After 
3 hours, cells were washed once with media, media replaced, and incubated overnight in 
the 37°C incubator.  
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Retroviruses were produced by transfection of 293T cells with plasmids 
expressing retroviral proteins Gag-Pol, G (VSV-G pseudotype), and either enhanced 
green fluorescent protein (EGFP) or the constructs with Lipofectamine 2000. As controls, 
retroviral or lentiviral vectors without an insert were used. Lentiviruses were produced by 
transfection of 293T cells with plasmids psPAX2, pMD2.G, and either EGFP or our 
constructs. At 48 hours after transfection, supernatants containing retrovirus were 
collected and frozen at -80°C. Cells were infected with twice diluted supernatant and 
10μg/mL polybrene overnight and washed, and selected with puromycin, 10 μg/mL 48 
hours after infection. Retroviral or lentiviral vectors expressing EGFP were used as an 
infection efficiency indicator: usually ∼80% of cells were fluorescent 2 days after 
infection. 
6. Immunoblotting 
Cells were washed twice with phosphate-buffered saline (PBS) and lysed in lysis 
buffer (40 mM HEPES, pH 7.5, 50 mM KCl, 1% Triton X-100, 1 mM Na3VO4, 50 mM 
glycerophosphate, 50 mM NaF, 5 mM EDTA, 5 mM EGTA, 1 mM PMSF, 1 mM 
benzamidine, and supplemented with a protease inhibitor cocktail (Roche). Xenografted 
tumor was snap-frozen in liquid nitrogen and then homogenized in the same buffer and 
centrifuged for 5 min at 1,000 × g, and supernatants were collected. Protein concentration 
of the lysates was measured with the Bio-Rad protein assay reagent, after which they 
were diluted with lysis buffer to achieve equal protein concentrations. Normalized protein 
samples were then electrophoresed on an SDS-PAGE gel (10% or 15% acrylamide-bis) 
and transferred to nitrocellulose membrane. Membranes blocked in 3% BSA and then 
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blotted with appropriate primary antibody overnight, washed three times with TBST, 
incubated with secondary antibody conjugated to horse radish peroxidase for 1 hour at 
room temperature, washed three times with TBST, and then developed using ECL 
solution and X-ray developer. 
7. β-galactosidase assay 
The -galactosidase assay was performed using X-gal (pH 6.0) as previously 
described (Gabai et al, 2009; Meng et al, 2010; Meng et al, 2011; Yaglom et al, 2007). 
Cells were plated at low density and were fixed with 2% formaldehyde plus 0.2% 
glutaraldehyde. The -galactosidase activity was determined by incubation with 1 mg/ml 
of solution of X-gal (5-bromo-4-chloro-3-indolyl -D-galactopyranoside) in 40 mM 
sodium citrate, 5 mM K3FeCN6, 5 mM K4FeCN6, 150 mM NaCl, 2 mM MgCl2 diluted in 
phosphate-buffered saline (at pH 6.0). The number of stained cells was counted from five 
randomly selected fields using a microscope and the proportion of stained cells was 
calculated. The results were expressed as mean value ± S.D. of three independent 
experiments.  
8. Luciferase Reporter Assays 
Cells were infected initially with HSE-luc,  NRF2-luc lentivirus, or the NF-κB 
luc-UB-GFP reporter ( a gift from Dr. Andrew Wilson), and then infected again with 
control or shHSP70 retrovirus, followed by puromycin selection. 3 days after selection, 
cells were either heat shocked at 45°C for 10 minutes (for HSF1) followed by 3 hour 
incubation at 37°C, or treated with 300 μM hydrogen peroxide for 5 hours (for NRF2). 
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After incubation period, the medium was aspirated, cells were washed twice with PBS, 
lysis buffer was added directly to the plate, and the plate was frozen at -80°C. Upon 
thawing, lysates were plated into 96 well plates. 50μl of luciferase assay reagent 
(Promega) was injected into each well and luminescence was read by luminometer. In 
parallel, lysates were plated into black 96 well plates and GFP fluorescence was read by 
the same luminometer. All measurements were done in triplicates, and the assays were 
repeated three times. 
9. Luciferase Refolding Assay 
Cells were co-infected with both EGFP and retroviral reporter encoding luciferase 
under the cytomegalovirus (CMV) promoter. For refolding assay, cells were subjected to 
heat shock at 45°C for 10 min, and then allowed to recover for the indicated time periods. 
At each time point, cells were washed in twice with ice-cold PBS, lysed with cell lysis 
reagent (Promega, San Luis Obispo, CA), and frozen at -80°C. Upon thawing, lysates 
were plated into 96 well plates. 50μl of luciferase assay reagent (Promega) was injected 
into each well and luminescence was read by luminometer. In parallel, lysates were 
plated into black 96 well plates and GFP fluorescence was read by the same luminometer. 
All measurements were done in triplicates, and the assays were repeated three times. 
10. Total RNA isolation, qRT-PCR, and microarray 
mRNA was isolated from cells using the RNeasy Mini Kit (Qiagen). In order to 
confirm knockdown of HSP70 before sending samples for microarray, a small mRNA 
aliquot was reverse transcribed with RetroScript Kit (Ambion), following manufacturer’s 
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instructions and quantitative Real-Time PCR (qRT-PCR) was performed using SYBR 
Green Rox Master Mix (Qiagen).  
Primers for human HSP70 were (Zaarur et al, 2006):  
Forward  5′-TGTTCCGTTTCCAGCCCCCAA-3′ 
Reverse  5′-GGGCTTGTCTCCGTCGTTGAT-5′  
Primers for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH):  
Forward 5′-GGCCTCCAAGGAGTAAGACC-3′,  
Reverse, 5′-AGGGGAGAGATTCAGTGTGGTG-3′  
mRNA from three sets of control and shHSP70 MCF7 cells were analyzed using 
Affymetrix GeneChip
®
 Gene 1.0 ST Array System for Human arrays, and two sets were 
used as the GSEA input. 
11. Flow Cytometry Protein Interaction Assay 
The assay procedure was adopted from previous reports (Blazer et al, 2010). In 
brief, biotinylated HSP70 was immobilized on polysterene streptavidin coated beads 
(Spherotech), incubated with Alexa-Fluor® 488 labeled BAG3 (50nM) and increasing 
amounts of YM-1 in buffer A (25mM HEPES, 5mM MgCl2, 10mM KCl, 0.3% Tween-20 
pH 7.5). Plates were incubated for 15 minutes then analyzed using a Hypercyt liquid 
sampling unit in line with an Accuri® C6 Flow Cytometer. Protein complex inhibition 
was detected by measuring median bead associated fluorescence. DMSO was used as a 
negative control and 1μM excess unlabeled HSP70 was used as a positive control.  
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12. GST-SH3 Library Pull Downs 
GST-fusion proteins encoding the SH3 domains of several proteins, or the 
cytosolic domain of CD40 (negative control), were immobilized on glutathione-
Sepharose (5 µg protein) and incubated with 1 -5 µl of IVT’d 35S-BAG3(∆B) protein in 
100µl wash buffer for one hour.  Beads were washed 3x in 142 mM KCl, 5mM MgCl2, 2 
mM EGTA, 0.5% NP40 20 mM HEPES (pH 7.7) and associated BAG3 (∆B) protein was 
analyzed by SDS-PAGE/autoradiography.  One-tenth input of the IVT 
35
S-BAG3(∆B) 
protein was loaded directly in the gel as a control.   
13. Co-Immunoprecipitation Assay 
For in vivo BAG3 associations, HEK293 or HeLa cells were transiently 
transfected with various plasmids. 24 hours after transfection, cells were lysed in 
immunoprecipitation buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 10 mM NaF, 2 mM Na3VO4, 2 mM PMSF, and 1% TritonX-100) supplemented 
with a mixture of protease inhibitors (Roche). Pre-cleared lysates were subjected to 
immunoprecipitation with FLAG (M2) antibody. Samples were rotated for 4 hours at 
4°C, followed by 1 h incubation with protein G PLUS-Sepharose Beads. The beads were 
then precipitated at 1000 x g, washed three times with lysis buffer, and proteins were 
eluted using SDS sample buffer. Immunoblot assays were performed as described. 
For effect of YM-1 on associations, HeLa cell extracts were prepared in M-PER 
lysis buffer (Thermo Scientific) and adjusted to 5mg of total protein in 1mL of extract. 
Equal 500μL samples were incubated with either a rabbit polyclonal for HSP70 (Santa 
Cruz H-300) or Goat IgG (Santa Cruz sc-2028). Samples received 5μL of DMSO (1%) or 
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5μL of YM-1 (5mM), making the final YM-1 concentration 50μM. Samples were gently 
rotated overnight at 4°C, followed by 4 h incubation with protein A/G-Sepharose Beads 
(Santa Cruz). The immunocomplexes were centrifuged at 1000 x g, washed 3 times with 
PBS pH 7.4. Precipitated proteins were eluted from the beads by boiling in SDS sample 
buffer, and separated by SDS-PAGE. Immunoblot assays were performed using the 
indicated antibodies. 
14. GST Pull Downs 
A total of 20 μg of purified GST-SRC-SH3 or GST alone was immobilized on 
glutathione–Sepharose (GE Healthcare). Immobilized GST-SRC-SH3 or GST was 
incubated for 4 hours at 4°C with HeLa cell lysates overexpressing BAG3 constructs 
prepared in buffer B (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.4% [vol/vol] NP-40, 10 
mM MgCl2, 5 mM EDTA, 2 mM DTT, protease and phosphatase inhibitors, 12 mM 
DTT, and 10 mM NaF). Beads were boiled in 2× sample buffer and analyzed by 
immunoblotting. 
15. Xenografts 
For establishing tumor xenografts, MCF7 cells were trypsinized and mixed at a 1:1 
ratio with Matrigel, and 1 million cells were injected subcutaneously into both left and 
right flanks of 6-week-old female NCR nude mice (Taconic). Tumor growth was 
monitored every other day using caliper and calculated according to the formula L × W
2
 × 
π/6, where L is length and W is width.  
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Chapter III.  Proteotoxicity is not the reason for the dependence of cancer cells on 
the major chaperone HSP70 
1. Introduction  
Major molecular chaperones, like HSP70, HSP90 or HSP27, and the transcription 
factor that regulates their expression, Hsf1, are often expressed in cancer cells at elevated 
levels (Calderwood et al, 2006; Ciocca & Calderwood, 2005; Santagata et al, 2011). In 
2007, the Lindquist and Mivechi groups discovered that certain types of cancer cannot be 
developed in Hsf1 knockout mice, thus starting a novel area in cancer research (Dai et al, 
2007; Min et al, 2007). More recently several publications reported that Hsf1 is critical 
for development of a variety of cancer at several stages (Dudeja et al, 2011; Gabai et al, 
2012; Meng et al, 2010; Xi et al, 2012). Interestingly, we reported that it is enough to 
knockout just one of the major chaperones, HSP70, to similarly block cancer 
development in the model of Her2-postive breast cancer (Meng et al, 2011). Overall, it 
was uncovered that Hsf1 and HSP70 are critical for the survival and growth of many 
types of cancer cells, but are dispensable for normal cells (Gabai et al, 2009; Meng et al, 
2011; Yaglom et al, 2007). For example, depletion of either HSP70 or Hsf1 in 
untransformed breast epithelial line MCF10A is not harmful. However, similar depletion 
in cells transformed with Her2 or PIK3CA oncogenes leads to growth arrest and overall 
senescence (Gabai et al, 2009; Meng et al, 2010).  
Following discovery of the essential role of Hsf1 in tumor development, a novel 
paradigm emerged called “non-oncogene-addiction” (Luo et al, 2009). According to this 
idea, tumor cells have increased demand for molecular chaperones due to elevated levels 
of abnormal proteins, which accumulate as a result of the toxic conditions associated with 
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the tumor microenvironment. This argument would not be valid in standard conditions of 
cell culture, where dependence on chaperones persists. On the other hand, cancer cells 
that are usually aneuploid have an imbalance in protein complexes, a characteristic which 
by itself may demand high levels of chaperones. This mechanism was proposed to 
explain why cancer cells become “addicted” to increased activity of Hsf1 and other 
chaperones (Solimini et al, 2007). This paradigm is widely accepted in the field and is 
supported by certain evidence. For example, aneuploid strains of yeast are sensitive to 
conditions that interfere with protein translation, folding and degradation (Pavelka et al, 
2010; Torres et al, 2010; Torres et al, 2007). Also, mammalian cell strains that have 
certain extra chromosomes demonstrate increased sensitivity to inhibitors of the 
chaperone HSP90 (Tang et al, 2011). This data, however, is circuitous, and a direct test of 
the model has not been carried out.    Here, we test the major prediction of the hypothesis 
that depletion of a major chaperone in cancer cells should reveal hidden proteotoxicity.  
These experiments were done using HSP70 as an example. 
Understanding why cancer cells become “addicted” to HSP70 is of fundamental 
importance. In fact, a number of small molecules that target HSP70 have been identified, 
and their further development requires clarity in question what domains and activities of 
HSP70 are specifically involved in cancer. If chaperone activity is critical, the peptide-
binding domain may be targeted. However, if the chaperone function is irrelevant other 
activities (e.g. interaction with co-factors) should be targeted. 
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2. Results 
A. HSP70 results in in cancer cell senescence. 
 
Previously we demonstrated that HSP70 suppresses oncogene-induced 
senescence (OIS) (Gabai et al, 2009; Meng et al, 2011; Yaglom et al, 2007). 
Accordingly, depletion of HSP70 in cancer cells lines led to induction of the cell cycle 
inhibitor p21, and triggered senescence and permanent growth arrest (Gabai et al, 
2009; Meng et al, 2011; Yaglom et al, 2007). Potentially these effects could be 
associated with triggering proteotoxic stress, for example due to aneuploidy-related 
protein imbalance. The major prediction of this model is that the overall chaperone 
capacity of cancer cells is limited due to the high levels of abnormal proteins, and 
thus depletion of HSP70 should trigger proteotoxic stress. To test this prediction, we 
probed the proteotoxic effect and the chaperone capacity in cancer cells following 
knocking down of HSP70 by monitoring different endpoints of proteotoxicity.  
As models, we chose MCF7 and HeLa cells, which have high levels of HSP70 
(Gabai et al, 2009; Yaglom et al, 2007). Furthermore, we previously used these cells 
to demonstrate effects of HSP70 on cell growth and senescence (Gabai et al, 2009; 
Yaglom et al, 2007).  When HSP70 was specifically depleted by retroviral shRNA 
expression, no changes in levels of the cognate HSC73 (HSPA8) were found in these 
cells, indicating the specificity of the knockdown (Yaglom et al, 2007). Under these 
conditions in MCF7 (and HeLa) cells, we observed a dramatic reduction of cell 
growth (Yaglom et al, 2007) and massive appearance of SA-β-gal-positive cells, 
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indicating senescence (Figure 11).  As noted previously, these effects were specific 
to transformed cells and were not seen in untransformed breast epithelial MCF10A 
cells (Gabai et al, 2009; Meng et al, 2011).  
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Figure 11. Depletion of HSP70 results in cancer cell senescence.  
SA-β-gal-positive cells following HSP70 depletion in MCF7 cells. Results shown are the 
mean and ±SEM of three independent experiments. Induction of the cell cycle inhibitor 
p21 and down-regulation of the mitosis factor survivin following HSP70 depletion is also 
shown. 
 
HSP70 
p21 
survivin 
β-actin 
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B. HSP70 knockdown does not result in proteotoxicity. 
 
As readout of proteotoxicity, we determined the levels of ubiquitinated proteins. 
Contrary to the predictions of the hypothesis, depletion of HSP70 did not significantly 
alter levels of ubiquitinated proteins (Figure 12), suggesting minimal buildup of abnormal 
species. Further, we evaluated activities of stress responsive transcription factors, Hsf1 
and Nrf2 in HSP70 depleted conditions. Hsf1 is activated by the buildup of abnormal 
proteins, while Nrf2 responds to reduced proteasome activity and oxidative stress. 
However, depletion of HSP70 did not cause activation of either Hsf1 or Nrf2 as assessed 
by corresponding promoter-luciferase reporter constructs in MCF7 or HeLa cells (Figure 
13 a, b), further suggesting the lack of proteotoxic stress. 
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Figure 12. HSP70 depletion does not alter ubiquitinylated protein levels.  
Depletion of HSP70 does not cause apparent change in ubiquitination. MG132 (left 
panel: MCF7- 5μM, 4hr; or right panel: HeLa- 10μM, 4hr) was used to inhibit the 
proteasome (positive ubiquitination control). All samples prepared in lysis buffer 
containing N-ethylmaleimide (NEM, 10mM). Samples were immunoblotted using an 
anti-ubiquitin antibody (lower panels). Upper panels: efficiency of HSP70 depletion. 
Representative blots of triplicate experiments are shown. Densitometry quantifying levels 
of ubiquitinated proteins in HeLa cells is shown at the bottom.   
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Figure 13. 
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Figure 13. HSP70 knockdown does not activate stress sensitive transcription factors, 
NRF2 or HSF1.  
 
(a) Depletion of HSP70 does not activate NRF2 luciferase reporter. Left panel: luciferase 
activity was measured at baseline or following hydrogen peroxide treatment (300μM, 6h) 
in MCF7 cells to mimic increased oxidative stress and normalized to baseline control. 
The means and ±SEM of three experiments are shown. (b) Depletion of HSP70 does not 
activate Hsf1 luciferase reporter. Luciferase activity was measured at baseline (0 hours) 
or 5 hours after heat shock (45°C, 10min) and normalized to baseline control. Left panel: 
MCF7 cells. Right Panel: HeLa cells. The means and ±SEM of three experiments are 
shown. 
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C. The refolding capability of cells is not altered in HSP70 depleted cells. 
 
Finally, we evaluated the ability of cells to refold luciferase, a folding substrate of 
HSP70 family members. Control and HSP70-depleted cells expressing luciferase were 
exposed to brief heat shock followed by recovery at 37
o
C. Under these conditions, 
luciferase becomes unfolded and inactivated followed by refolding and resumption of 
catalytic activity. HSP70 depletion did not affect either the level of luciferase refolding or 
its kinetics in either MCF7 or HeLa cells (Figure 14). Therefore, the chaperone capacity 
of cells appears to be not markedly reduced by depletion of HSP70. This data indicates 
that in HSP70 depleted cells, other chaperones (e.g., HSC70 or other HSP70 family 
members) can substitute for HSP70 and there is no significant proteotoxicity. 
Accordingly, dramatic effects of HSP70 on the cancer cell growth are unlikely to be 
caused by proteotoxic stress, convincing us to search for other effects of this chaperone 
on cancer cell biology. 
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Figure 14. Cancer cell chaperone capacity is not perturbed by HSP70 depletion.  
HSP70 knockdown does not affect luciferase refolding. Cells were heat shocked at 45°C 
for 10min, and luciferase activity was measured over time (left panel- MCF7, right panel- 
HeLa). Plot shows mean and ±SEM (n=3). 
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3. Discussion 
Interestingly, we previously reported that proteotoxic stress is not seen upon 
depletion in cancer cells of another chaperone HSP27 (O'Callaghan-Sunol et al, 2007). 
This example using HSP27 did not represent a very strong argument against the model of 
proteotoxicity simply because the HSP27 may have a relatively narrow chaperone 
specificity, which may not be revealed by general proteotoxic measurements. With 
HSP70, however, the situation is different, since it is known to have a very wide range of 
substrates, and lack of evidence of proteotoxicity under the conditions that trigger 
senescence indicates that cancer cell growth is not associated with internal proteotoxicity.  
Accordingly the reason for the dependence of cancer cells on HSP70 must be 
different from that of its chaperone capacity. It may be related to the function of HSP70 
in cancer signaling. In fact, we and others have reported that depletion of HSP70 leads to 
dramatic changes in multiple signaling pathways involved in cancer. For example, 
HSP70 has been implicated in control of JNK and ERK pathways, and chaperone 
function was dispensable for these regulations (Yaglom et al, 2003; Yaglom et al, 1999). 
Communication with cancer-related signaling pathways may be mediated by various co-
factors of HSP70, like DnaJ or Bag family members. Therefore, drug design efforts 
should be directed towards these protein interactions of HSP70.  
These data, while suggesting targeting the signaling function of HSP70, do not 
negate possible beneficial effects of targeting the chaperone capacity of cells, e.g. by 
inhibiting the folding function of multiple members of the HSP70 family. Indeed, 
86 
 
 
aptamers that inhibit the peptide-binding domain of HSP70 demonstrated anti-cancer 
effects (Rerole et al, 2011), and cancer cells were specifically sensitive to treatments that 
enhance proteotoxicity, like puromycin (Neznanov et al, 2011). Therefore, the possibility 
is that inhibition of the signaling function should be combined with inhibition of the 
chaperone function. 
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Chapter IV.  HSP70-BAG3 Module Regulates Cancer-Related Signaling Networks 
1. Introductions 
Several groups have explored the mechanisms by which cancer cells become 
addicted to HSP70. On their path to tumorigenesis cells must escape apoptosis (Hanahan 
& Weinberg, 2011), anoikis (Kim et al, 2012b) and the harsh conditions of the tumor 
microenvironment (Luo et al, 2009). Although elevated levels of HSP70 have strong anti-
apoptotic activity (Beere et al, 2000a; Garrido et al, 2006), it is not yet clear whether this 
function is important for its role in cancer. 
The finding that HSP70 suppresses cellular senescence has established a clear 
connection to cancer.  Senescence is defined as irreversible cell growth arrest that is 
associated with assorted cellular changes in morphology and gene expression (Itahana et 
al, 2004; Shay & Roninson, 2004b). Certain oncogenes may trigger senescence, 
oncogene-induced senescence (OIS) (Bihani et al, 2007; Olsen et al, 2002; Wajapeyee et 
al, 2008), which provides defense against cancer. We have demonstrated that depletion of 
HSP70 activates senescence in cells transformed by the oncogenes Her2, PIK3CA and 
RAS, but that it has minimal effects in normal cells (Gabai et al, 2009; Yaglom et al, 
2007). Accordingly, HSP70 knockout mice did not develop breast cancer upon 
expression of Her2 oncogene (Meng et al, 2011). Therefore, HSP70 could be critical for 
the escape of transformed cells from OIS, a property that defines its role in tumor 
initiation.  
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These properties of HSP70 suggest that it could be used as a drug target. There 
have been several attempts to develop inhibitors of HSP70 for cancer treatment, 
including inhibitors of substrate binding, e.g. aptamers (Rerole et al, 2011) or pifithrin μ  
(Leu et al, 2009; Leu et al, 2011; Miyata et al, 2012; Strom et al, 2006), or compounds 
that interact with the ATPase domain, such as VER155008 (Massey et al, 2010), MAL3-
101 (Huryn et al, 2011), and YK-5 (Rodina et al, 2013). However, development of these 
inhibitors has not reached the clinical trial stage.  
In order to tailor inhibitor development to cancer specificity, specific mechanisms 
underlying the effects of HSP70 on tumor development should be defined. In search for 
these mechanisms, we focused on a nucleotide exchange factor BAG3. Bag proteins all 
contain at least one copy of a roughly 50 amino acid evolutionarily conserved domain, 
the “bag-domain”, that allows them to interact with and regulate HSP70 (Takayama & 
Reed, 2001b). Beyond the Bag domain, the Bag-family proteins contain other motifs and 
domains, allowing them to interact with different target proteins and thus have different 
functions (see Table 5).  Of the six Bag family members, BAG3 is the only member to 
contain well characterized protein-protein interaction motifs- PxxP and WW domains 
(Takayama & Reed, 2001b), which may connect it to SH3 domains and PPxY motifs of 
signaling proteins, respectively (see Figure 15) (Ingham et al, 2005; Li, 2005).  
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Table 5. The Bag Family of Proteins 
Name Aliases Localization Comments References
Bag1 Rap46
nucleus/  
cytosol
Enhances the anti-apoptotic effects of Bcl-2   
Inhibits Hsp70 refolding                     
Coordinates mitogenic and cell stress 
signals via interaction with Raf-1 and Hsp70            
Direct proteins towards degradatoin
Takayama et al, 1995 
Nollen et al, 2000             
Song et al, 2001     
Tsukahara et al, 2010             
Bag2 cytosol
Inhibits CHIP ubiquitination of Hsp70 
substrates
Che et al, 2013                
Dai et al, 2005
Bag3
CAIR-1        
BIS           
MFM6
Cytosol
Synergizes with Bcl-2 (anti-apoptotic)            
Modulates cell adhesion and motility                          
Stimulates macroautophagy                  
Lee et al, 1999   Kassis 
et al, 2006                
Iwasaki et al, 2007               
Carra et al, 2008
Bag4 SODD cytosol
Associates with TNF-R1 and extrinsic 
apoptosis pathway signaling                          
Jiang et al, 1999
Bag5 cytosol
Inhibits Parkin E3 ligase activity                     
Inhibits CHIP activity
Kalia et al, 2004                          
Ying et al, 2013
Bag6
BAT3                  
Scythe                      
cytosol
Modulates Reaper Induced Apoptosis                                             
Stabilizes AIF                                      
Ubiquitination/degradation of newly 
synthesized defective proteins                     
Targets mislocalized proteins for 
degradation
Thress et al, 1998    
Desmots et al, 2008   
Minami et al, 2010       
Claessen et al, 2014                       
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Figure 15. The Bag Family of Proteins Domain Structure. 
The six members of the Bag family of proteins each have a BAG domain at their C-
terminus which enables binding to the HSP70 NBD domain. Bag1, Bag1L (long version), 
and Bag6 contain an ubiquitin-like domain (UB). Bag1L contains a nuclear localization 
sequence (NLS). BAG3 also has protein interaction domains- WW domain and PxxP 
domains, and an M domain where small HSPs are known to bind. Adapted from 
(Takayama & Reed, 2001a).  
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BAG3 has been implicated in macroautophagy and aggresome formation (Carra et 
al, 2008; Gamerdinger et al, 2011; Ulbricht et al, 2013). In both processes BAG3 was 
proposed to link complexes of HSP70 with protein aggregates to the autophagic and 
aggresome machineries. While it is unknown how BAG3 interacts with the latter, in the 
process of autophagy BAG3 uses its WW domain to interact with one of the organizers of 
the autophagic vacuole SYNPO2 (Ulbricht et al, 2013). In addition to its function in 
recruitment of the HSP70-bound cargo, it was demonstrated that BAG3 can interact with 
signaling factors via its PxxP motif (e.g. with PLCγ) (Doong et al, 2000) or WW domain 
(e.g. with components of Hippo pathway LATS1 and AMOT1) (Ulbricht et al, 2013). 
Since BAG3 has been implicated in cancer cell motility and invasion (Iwasaki et al, 
2007; Kassis et al, 2006; Suzuki et al, 2011), there is a possibility that these effects result 
from regulation of signaling pathways by BAG3. Interestingly, in the previous studies the 
effects of BAG3 on signaling were not connected to effects of HSP70 on these pathways. 
Here, we hypothesized that BAG3 could serve as a scaffold with the potential for 
integrating HSP70 levels and multiple cancer signaling pathways, and thus mediate 
effects of HSP70 on cancer. 
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2. Results 
A. BAG3 mediates effects of HSP70 on SRC activity. 
 
In order to uncover the role of BAG3 and its association with HSP70 in cancer, 
we sought to identify SH3 domain-containing signaling factors that can interact with the 
PxxP motif of BAG3. Accordingly, we performed pull down experiments using a series 
of recombinant SH3 domains of various proteins fused to GST. GST-CD40 lacking the 
SH3 domain was used as a negative control. Lysates with in-vitro-translated S
35
-labeled 
BAG3 were passed over beads carrying various SH3-GST fusion proteins, and bound 
BAG3 was detected. In the pull down experiment, BAG3 interacted with SH3 domains of 
PLCγ, SRC, c-Abl, c-Grap, Nck, Crk, RasGAP, n-Grab2, and c-Grab2 (Figure 16a). 
Many of these proteins are components of cancer-related pathways, highlighting the 
potential of BAG3 as a master regulator of cancer signaling. We further chose SRC as an 
example to explore mechanistically how BAG3 regulates signaling.  
First we confirmed that the full length SRC protein interacts with BAG3 in cells. 
FLAG-labeled BAG3 was co-expressed with SRC in 293T cells, precipitated with anti-
FLAG antibody, and SRC was probed on the blot with anti-SRC antibody. Figure 
16b:left panel shows that SRC effectively associated with BAG3. A similar experiment 
was done in HeLa cells to detect association of BAG3 with endogenous SRC (Figure 
16b: right panel). 
Since BAG3 is a co-factor of HSP70, we further assessed how the ability to 
interact with HSP70 influences association of BAG3 with the SH3 domain of SRC. 
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Various constructs of BAG3 were expressed, cell lysates were incubated with beads 
carrying recombinant SH3 domain of SRC, and bound BAG3 molecules were detected by 
immunoblotting. Besides a full length BAG3 construct, we tested deletions of the PxxP 
and Bag domains (referred to as FL, ΔPxxP and ΔB, respectively), as well as an R480A 
mutation, which impairs BAG3 binding to HSP70 (Gentilella & Khalili, 2011) (Figure 
16c). The inability of the ΔB and R480A constructs to bind to HSP70 was confirmed in 
the pull down experiment (Figure 16d). The full length BAG3 effectively interacted with 
the SH3 domain of SRC, and binding was strongly reduced by deletion of the PxxP 
domain, as expected (Figure 16e). Importantly, both ΔB and R480A constructs also 
demonstrated reduced binding to the SRC-SH3 domain compared to the full length 
BAG3, and the effects of these mutations were comparable to the effect of the PxxP 
deletion (Figure 16e). Therefore, interaction with HSP70 appears to be critical for 
binding of the PxxP domain of BAG3 with the SH3 domain of SRC.   
These findings, that the interaction of BAG3 with the SH3 domain of SRC 
requires the association with HSP70, suggest that BAG3 may serve as a scaffold, 
mediating the effects of HSP70 on signaling pathways, including SRC. In line with this 
hypothesis, knockdown of HSP70 led to significant activation of SRC, as judged by its 
Y416 phosphorylation (Figure 17a). Furthermore, depletion of HSP70 increased 
phosphorylation of downstream SRC targets paxillin and p130Cas (Figure 17b), 
confirming SRC activation. Interestingly, knockdown of BAG3 did not activate SRC, 
however it prevented activation of SRC upon depletion of HSP70 (Figure 16a). 
Therefore, (i) HSP70 can regulate SRC activity, and (ii) this regulation requires BAG3.  
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Interaction with BAG3 must inhibit SRC since depletion of HSP70 activates it 
(Figure 17a).  Accordingly, overexpression of BAG3 mutants that are unable to bind 
HSP70 should mimic the effects of HSP70 depletion on SRC. While overexpression of 
the full length BAG3 did not affect SRC activity, overexpression of either the ΔB or 
R480A constructs significantly activated endogenous SRC in either HeLa or MCF7 cells 
(Figure 17c), further supporting the model.  
  
95 
 
 
 
Figure 16. BAG3 interacts with SRC and this interaction is regulated by HSP70.  
 
(a) BAG3 interaction with SH3 domains of various proteins, see Results. (b) Left panel: 
Co-immunoprecipitation of BAG3 with full length SRC in 293T cells. Relatively low 
abundance of SRC in this cell line necessitated overexpression of SRC for IP as well as 
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FLAG tagged BAG3. Cells were collected and lysed 24 hours after transfection. Negative 
controls included GFP only (control) or SRC only (-FL-BAG3). Middle lane FL-BAG3 
had expression of both FLAG-tagged BAG3 and SRC. IP was done using FLAG 
antibody. Right panel: Co-immunoprecipitation of full length SRC with FLAG-tagged 
BAG3 in HeLa cells. Cells were transfected with either FL-BAG3 or GFP (control), and 
immunoprecipitated using FLAG antibody. Association with HSP70 is also shown (upper 
band indicated by arrow); lower band is the IgG heavy chain. (c) Schematic of BAG3 
constructs used in this study, including wild type (FL), Bag domain deletion (ΔB), Bag 
domain point mutation (R480A), and PxxP domain deletion (ΔPxxP). All constructs 
contain an N-terminal FLAG tag. Domains are depicted including Bag domain (HSP70 
binding domain), PxxP motif, M domain (small heat shock protein binding domain), and 
WW domain. (d) Co-immunoprecipitation of HSP70 with FLAG-tagged BAG3 
constructs. HeLa cells were transfected with GFP (control) or indicated BAG3 constructs, 
and immunoprecipitated with anti-FLAG antibody. HSP70 is the upper band indicated by 
the arrow. The large lower band in the HSP70 IP blot is the IgG heavy chain. (e) GST 
pull down of BAG3 constructs with SH3 domain of SRC. HeLa cells were transfected 
with indicated constructs, and after 24 hours, cell lysates were prepared and incubated 
with the purified GST-SH3 domain (from SRC) bound to agarose beads or GST beads 
alone for 4 hours. BAG3 associated with the SRC SH3 domain was analyzed via 
immunoblot with anti-FLAG antibody.  
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Figure 17. 
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Figure 17. HSP70 affects SRC activation in cells.  
a) HSP70 depletion activates SRC in a BAG3-dependent manner. MCF7 cells were 
infected with control, shHSP70, shBAG3, or dual shHSP70 and shBAG3 retroviruses and 
immunoblotted for activated SRC (p-Y416). (b) Effects of shHSP70 and shBAG3 on the 
downstream SRC targets. Cells were treated for 30 minutes with 1mM sodium 
orthovanadate prior to lysis. (c) Expression of BAG3 mutants that cannot bind HSP70 
leads to activation of SRC. BAG3 constructs or GFP were transfected into HeLa or 
MCF7 cells. Cells were lysed after 24 hours and immunoblotted for activated SRC (p-
Y416). Representative blots of two experiments for each cell line are shown.  
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B. HSP70-BAG3 module affects NF-kB. 
 
Upon establishing the general mechanistic principle that that HSP70 and BAG3 
can cooperate in direct regulation of signaling factors, we further sought to identify a 
spectrum of cancer-controlling signaling factors regulated by the HSP70-BAG3 module. 
We used a combination of two general criteria for such regulation: the signaling factor 
should be affected (i) by HSP70 and BAG3 depletion, and (ii) by overexpression of the 
ΔB or R480A BAG3 constructs but not of the normal BAG3. 
In this search, we utilized our prior data, where we used microarray analysis to 
compare gene expression in control and HSP70-depleted MCF7 cells (Figure 18a), 
followed by Gene Set Enrichment Analysis (GSEA). The GSEA-based signal pathway 
analysis software was developed by the Broad Institute. According to their manual, 
pathways that show a false discovery rate (FDR) less than 0.25 are significant enough to 
warrant validation. Our analysis indicated that a large number of pathways were 
predicted to be up- or down-regulated by HSP70. For example, the proteasome and 
ubiquitin pathways were strongly up-regulated and received the highest scores (see 
Figure 18b.). Another pathway that received a high score was NF-kB (Figure 18c. upper 
left) and related pathways, such as the IL-1R, or TNF pathways (Figure 18c. lower left 
and upper right). Indeed, using a luciferase reporter under the control of NF-kB, we 
confirmed that NF-kB activity was increased in HSP70-depleted cells, (Figure.18d). 
Also, levels of I-kB were reduced while phosphorylation of the p65 subunit of NF-kB 
was elevated (Figure 18e.).  
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We then tested if BAG3 is involved in regulation of NF-kB by HSP70. 
Accordingly, BAG3 was depleted in MCF7 cells using shRNA, and activity of NF-kB 
was assessed using the luciferase reporter. Unlike HSP70, depletion of BAG3 had little 
apparent effect on the activation of NF-kB (Figure 18d), the levels of phosphorylated NF-
kB p65 subunit (p-S536) and of IκB (Figure 18e). On the other hand, in cells with BAG3 
depletion, the ability of the knockdown of HSP70 to activate NF-kB was strongly 
reduced (Figure 18d). Therefore, as with SRC regulation, the HSP70-BAG3 module is 
critical for regulation of NF-kB. 
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Figure 18. 
102 
 
 
Figure 18.  HSP70 depletion affects multiple signaling pathways.  
(a) HSP70 mRNA levels in triplicate samples sent for microarray and subsequent GSEA. 
Bars represent ±SEM. (b) HSP70 depletion activates proteasome pathway. GSEA 
Proteasome pathway enrichment plot shown.  NES- Normalized Enrichment Score. FDR- 
False Discover Rate. (c) HSP70 depletion activates NF-kB pathway. GSEA RelA 
pathway (upper left), TNF pathway (upper right), and IL-R (lower left) enrichment plots. 
(d) Effect of HSP70 on NF-kB depends on BAG3. MCF7 cells were infected with Rel-A 
luciferase lentiviral reporter, followed by infection with shBAG3, shHSP70, or empty 
vector control retroviruses, as indicated. Levels of luciferase activity were measured and 
normalized to GFP. Results are shown as means and ±SEM of triplicate experiments. 
Dual depletion of HSP70 and BAG3 results are mean and ±SEM of duplicate 
experiments. (e) Effect of HSP70 or BAG3 depletion on NF-κB pathway members in 
MCF7 cells analyzed by immunoblotting. P-p65 is p- NF-κBp65-Ser536.  
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C. Effects of the HSP70-BAG3 module on other cancer-related signaling factors. 
 
Since the unbiased approach with GSEA produced only limited information about 
signaling network regulated by the HSP70-BAG3 module, in further search for factors 
regulated by this module, we utilized a more biased approach based on hints obtained in 
our prior findings. Accordingly, we decided to test if the regulation of previously 
identified HSP70-controlled signaling factors also involved BAG3. In studies of the 
oncogene-induced senescence and tumor initiation, we reported that depletion of HSP70 
affects two important signaling proteins that control growth of cancer cells, the cell cycle 
inhibitor p21, and the regulator of mitosis, survivin (Gabai et al, 2009; Meng et al, 2011).  
To test if BAG3 is also involved in control of these factors, we investigated whether 
depletion of BAG3 in MCF7 using shRNA affects levels of p21 and survivin. As with 
knockdown of HSP70, BAG3 targeting resulted in decreased levels of survivin, and 
accumulation of p21 (Figure 19a: upper panel). Similar effects of HSP70 and BAG3 
depletion were seen in HeLa cells (Figure 19b) and the colorectal carcinoma cell line, 
HCT116 (Figure 19c), demonstrating that these effects are related to multiple cancer 
types. BAG3 depletion paralleled the effects of HSP70 knockdown in all three cell lines, 
further supporting the idea that HSP70 and BAG3 are co-regulators of these pathways. In 
line with this suggestion, overexpression of the ΔB and R480A BAG3 mutants, but not 
normal BAG3, in HeLa cells mimicked effects of HSP70 depletion on survivin (Figure 
19d). In this experiment we were unable to assess effects on BAG3 mutants on p21, since 
levels of this protein in HeLa cells were undetectable. 
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Since both p21 and survivin have a common regulator major transcription factor 
FoxM1, we tested whether the HSP70-BAG3 module can control this cancer-regulating 
factor. Depletion of either HSP70 or BAG3 led to strong down-regulation of FoxM1 
(Figure 19a: upper panel) and of its distinct downstream target, the  cell cycle inhibitor 
p27 (Wang et al, 2005) in MCF7 cells, and the effect on FoxM1 was seen in HeLa 
(Figure 19b) and HCT116 cells (Figure 19c) as well. Furthermore, while the levels of 
FoxM1 were unaltered in normal BAG3 and empty vector control conditions, the ΔB or 
R480A BAG3 mutants caused strong down-regulation of FoxM1 (Figure 19d), indicating 
the importance of HSP70-BAG3 interaction in expression of this major transcription 
factor. Since FoxM1 plays multiple roles in OIS, metastasis and invasion, these findings 
further support a broad role for the HSP70-BAG3 module in tumorigenesis.  
Based on our prior study that connected the stress response to the translation 
factor HuR, another major player in cancer development (Gabai et al, 2012), we also 
suggested that HSP70-BAG3 module may affect this pathway. Depletion of either HSP70 
or BAG3 led to significant down-regulation of HuR in all cell lines tested (Figure 19a: 
upper panel, 19b, and 19c). Furthermore, while the levels of HuR were unaltered in 
normal BAG3 and empty vector control conditions, the ΔB or R480A BAG3 mutants 
caused strong down-regulation of HuR, indicating that interaction between HSP70 and 
BAG3 is important for regulation of this major cancer regulator (Figure 19d). 
Additionally, we considered whether one of HuR’s translational targets, HIF1, which is a 
major transcription factor involved in cancer, might also be down-regulated.  Since levels 
of HIF1 depend on the availability of oxygen, control, HSP70-depleted and BAG3-
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depleted cells were treated with either hypoxia mimetic deferoxamine (DFO), or 
proteasomal inhibitor MG-132, both of which stabilize HIF1. HSP70-depleted or BAG3-
depleted MCF7 cells had significantly reduced levels of HIF1 compared to control cells 
(Figure 19a lower panel). Furthermore, HSP70 depletion strongly reduced expression of a 
major HIF1 downstream target gene VEGF (Figure 19e). Therefore, it appears that the 
entire signaling network that controls multiple processes in cancer development, 
including growth, invasion and angiogenesis, involving HuR, HIF1 and VEGF is 
regulated by BAG3 and HSP70. 
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Figure 19. 
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Figure 19. HSP70 and BAG3 Modulate a Complex Network of Signaling Pathways. 
(a) Effect of HSP70 or BAG3 depletion on cancer related pathways in MCF7 cells. 
Portions of cells were treated with DFO (100μM, 4h) or MG132 (5μM, 4h). Blots are 
representative of triplicate experiments. (b) Effect of shHSP70 and shBAG3 on pathways 
in HeLa cells. Blots are examples from triplicate experiments. (c) Effect of HSP70 or 
BAG3 knockdown in HCT116 cells. (d) Expression of BAG3 mutants that cannot bind 
HSP70 leads to inactivation of survivin, FoxM1, and HuR. BAG3 constructs were 
transfected into HeLa cells, and after 48 hours, cells were lysed and immunoblotted for 
indicated proteins. Blots are representative of triplicate experiments. (e) Levels of VEGF 
were determined in supernatant as described (Gabai et al, 2012). 
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In summary, the HSP70-BAG3 module is involved in regulating a complex 
network of pathways, including SRC, NF-kB, FoxM1, survivin, p21, p27,
 
HuR, HIF1 and 
most likely other pathways, all of which play a role in cancer development. When 
individually considered, these pathways could have cancer-promoting or cancer-
repressing effects. Nevertheless, we know that in breast cancer models, depletion of 
HSP70 suppresses both tumor initiation and progression (Meng et al, 2011), indicating 
that the net outcome of this complex HSP70-BAG3-controlled signaling network to be 
pro-oncogenic. It should also be noted that only with SRC did we identify a direct 
connection to the HSP70-BAG3 module biochemically. With other pathways, genetic 
data do not establish the direct interaction, and therefore these interactions could be 
mediated by additional factors that can bind to WW or PxxP motifs on BAG3.  
  
109 
 
 
D. Disruption of the HSP70-BAG3 complex by a small molecule mimics effects of 
HSP70 depletion on signaling and cancer. 
 
 Here, we predicted that blocking interaction between HSP70 and BAG3 could 
mimic depletion of HSP70 and have anti-cancer effects. We focused on an inhibitor of 
HSP70, termed YM-1 (Rousaki et al, 2011; Wang et al, 2013). To test if YM-1 might 
disrupt the HSP70-BAG3 interaction, Jason Gestwicki’s group immobilized HSP70 on 
beads and measured its binding to fluorescently-labeled BAG3 using a flow cytometry 
protein interaction assay (FCPIA). YM-1 strongly inhibited the interaction between 
HSP70 and BAG3 (IC50 ~ 5 µM; Figure 20a). This activity was consistent with the ability 
of YM-1 to bind a conserved, allosteric pocket in HSP70, which traps the chaperone in an 
ADP-bound form that has weak affinity for BAG3 (Rousaki et al, 2011; Wang et al, 
2013). Further, to test if YM-1 can disrupt the HSP70-BAG3 interaction in cells, HSP70 
was immunoprecipitated from HeLa cells treated with YM-1 or a vehicle control, and 
immunoblotted for BAG3. YM-1 almost completely blocked binding of HSP70 to BAG3 
in cells (Figure 20b), indicating that YM-1 is a good chemical probe for addressing the 
importance of the HSP70-BAG3 interaction in cancer signaling.  
Next, we treated MCF7 and HeLa cells with YM-1 and the activities of signaling 
pathways were assessed. In order to determine the appropriate dosage, a range of 
concentrations were tested (Figure 20c). The concentrations of YM-1 used for testing 
effects on signaling pathways are described in the legend to Figure 20, but represent the 
minimal dose necessary to see an effect in the appropriate cell line. As predicted, YM-1 
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diminished the FoxM1 and HIF1 pathways, while activating SRC (Figure 20d), further 
supporting a role for the HSP70-BAG3 interaction in cancer signaling.  
Additionally, we asked whether YM-1 might modify triage of clients from HSP70 
to HSP90, and therefore HSP90 client protein stability. The Chiosis group recently 
presented a compound (YK5) that also happens to bind to an allosteric pocket of HSP70, 
which is close to but distinct from the YM-1 binding pocket. YK5 was shown to inhibit 
HOP and HSP90 association with HSP70 and so resulted in degradation of HSP90 client 
proteins (Rodina et al, 2013). Using HeLa cells treated with increasing concentrations of 
YM-1, we looked to see if there was any change in Raf-1 or Akt (well established HSP90 
clients) total protein levels (Figure 20e). YM-1 did not alter the degradation of either Raf-
1 or Akt, indicating that YM-1 does not alter passing of client proteins from HSP70 to 
HSP90.   
As a further test of this model, we examined the effects of the small molecule 
inhibitor myricetin, which inhibits HSP70 through a different mechanism that involves 
the HSP40 family of co-chaperones (Chang et al, 2011), and does not hinder BAG3 
binding to HSP70. Unlike YM-1, myricetin had no significant effects on the signaling 
pathways (Table 1). Together this data highlights the specificity of YM-1 for the HSP70-
BAG3 interaction and its role in modifying signaling networks. 
Since many of the HSP70-BAG3-regulated pathways affect cell growth and 
survival, and depletion of HSP70 is detrimental for cancer cells specifically due to 
oncogene signaling (Meng et al, 2011), we compared effects of YM-1 on viability of non-
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transformed MCF10A human breast epithelial cells and MCF10A derivatives 
transformed with either Her2 or PIK3CA oncogenes (Figure 21a). Here, cells expressing 
oncogenes were more sensitive to YM-1 than untransformed MCF10A cells (Figure 21a).  
To test the effects of YM-1 in vivo, we used the xenograft model with MCF7 
cells, which we previously showed lose the ability to develop tumors upon depletion of 
HSP70 (Meng et al, 2011). MCF7 cells were transplanted subcutaneously into nude mice, 
and when tumors reached the palpable stage, animals were injected intraperitoneally with 
25mg/kg YM-1 or saline. The injections were done three times every second day, and 
tumor growth was monitored via calipers. Figure 21b shows that administration of YM-1 
dramatically inhibited tumor growth. There were no apparent effects of the drug on the 
health and vitality of the animals at the effective doses used. In fact, they were more alert 
than untreated animals due to the lower tumor burden. The inhibition of tumor growth by 
the drug closely correlated with suppression of FoxM1, down-regulation of survivin and 
induction of p21 (Figure 21c). The HIF1 pathway could not be assessed in this 
experiment since the levels of HIF1 were undetectable in either naïve or YM-1-treated 
animals. Therefore, YM-1 showed a predictable response in animals, which correlated 
with almost complete suppression of tumor growth with minimal normal tissue toxicity.  
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Figure 20. 
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Figure 20. YM-1 inhibits the HSP70-BAG3 interaction and mimics effects of HSP70 
depletion on signaling. 
(a) YM-1 disrupts the HSP70-BAG3 interaction by FCPIA. Experiments were performed 
in triplicate, normalized and combined; the error bars represent the standard error of the 
mean. (b) YM-1 disrupts HSP70-BAG3 interaction in cells. Co-immunoprecipitation of 
HSP70 and BAG3 from HeLa cell lysates showed that YM-1 inhibits formation of the 
HSP70-BAG3 complex. (c) Dose dependent effect of YM-1 select pathways in HeLa 
cells (left) or MCF7 cells (right). The concentration of YM-1 is given in μM above the 
appropriate lane; DMSO control indicated by “C”. (d) YM-1 mimics effects of HSP70 
depletion on signaling pathways. Left panel: Hela cells were treated with YM-1 (5 μM) 
for 48 hours, and cell lysates analyzed for levels of indicated components of signaling 
pathways by immunoblotting. Top middle panel: HeLa cells treated with YM-1 were also 
treated with DFO (100μM) before lysis to visualize effect on HIF1. Lower middle panel- 
MCF7 cells were treated with YM-1 (10 μM) in the presence of DFO (100μM) and then 
lysed to evaluate levels of HIF1. Right panel: MCF7 cells treated with YM-1 (10μM, 48 
h) (e) Effect of YM-1 on HSP90 clients. HeLa cells were treated with varying 
concentrations of YM-1 over 24 and 48 hours: 1- DMSO control, 2- 0.2μM, 3 – 0.5μM, 4 
- 1μM, 5 – 2μM, 6 – 5μM. Cell lysates were then analyzed for levels of indicated proteins 
by immunoblotting. Blots are representative of duplicate experiments. 
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Table 6. Comparison of the effect of compounds on signaling networks to HSP70 
depletion.  
 
shHSP70 YM-1 Myricetin 
FoxM1 ↓ ↓ - 
p21 ↑ ↑ - 
HuR ↓ ↓ - 
HIF1 ↓ ↓ - 
p-SRC ↑ ↑ - 
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Figure 21. YM-1 inhibits tumor growth. 
(a) Oncogene-expressing cells are more sensitive to YM-1 than un-transformed cells. 
MTS assay showing effect of YM-1 on wild type (control) or transformed MCF10A cell 
viability.  Means and ± SEM of triplicate experiments are shown. (b) Nude mice were 
subcutaneously injected bilaterally in hind flanks with MCF7 cells in matrigel. Once 
tumors were palpable mice were randomly selected and injected with saline (control: n=7 
mice) or YM-1 (25mg/kg; n=7 mice) once every other day for three days. Plot shows 
tumor growth over time of control tumors (12 tumors/7 mice treated with saline; two 
tumors did not take) and tumors treated with YM-1 (14 tumors/7 mice treated with YM-
1).  Solid lines are control tumors. Dotted lines are YM-1 treated. Error bars designate 
±SEM. (c) Two tumors from above mice were taken after last injection and analyzed by 
immunoblot for effect on FoxM1 pathway. 
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In an effort to improve upon YM-1 several derivative compounds were created in 
order to improve the efficacy of HSP70/BAG3 inhibition, including JG-84 and JG-98. 
One compound, JG-36 was included as a negative control as it has a similar structure to 
YM-1, but has a lower affinity for the HSP70 binding pocket, and therefore does not 
inhibit the BAG3/HSP70 complex. HeLa cells were treated with varying concentrations 
of YM-1, JG-36, JG-84, or JG-98 and the effect on the previously described signaling 
networks (FoxM1, survivin, and HuR) was assessed (Figure 22). Alterations in these 
signaling pathways were not seen until 48 hours, and so the 24 hour data is not shown. As 
expected, because JG-36 could not inhibit HSP70/BAG3 complex formation, no effect 
was seen on any of the pathways. Additionally, both JG-84 and JG-98 were more potent 
compounds than YM-1, showing the anticipated changes in pathways, but using much 
lower dosages (between 0.5-1μM for JG-84 and JG-98 compared to 5μM for YM-1). 
Together this data indicates that YM-1 impairment of BAG3-HSP70 association is 
responsible for the changes in signaling networks since JG-36 (a structural analog) had 
no effect. Additionally, it is possible to create derivatives of YM-1 with increased 
efficacy, such as JG-84 and JG-98 that have potential for future development into viable 
drug candidates. 
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Figure 22. YM-1 derivatives are more potent.  
HeLa cells were treated with varying dosages of compounds. Cell lysates were collected 
and analyzed via immunoblotting after 24 and 48 hours. The 48 hour time point is shown. 
C- DMSO control. Blots are representative of duplicate experiments.   
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3. Discussion 
Here we investigated potential mechanisms of regulation of cancer signaling by 
HSP70. We specifically focused on BAG3, the member of the Bag family proteins which 
functions in HSP70 nucleotide exchange. The focus was defined by prior reports that 
BAG3 can interact with signaling molecules, via its PxxP and WW domains. In other 
words, via its Bag domain BAG3 may regulate the chaperone activity of HSP70 by 
controlling the ADP/ATP exchange, and via PxxP and WW motifs it can also regulate 
activities of important signaling pathways. Therefore BAG3 may potentially be able to 
integrate the HSP70 chaperone network with a network of signaling pathways.  Using 
both biochemical and genetic approaches, we demonstrated that effects of HSP70 in 
regulation of signaling are mediated by BAG3. Surprisingly, while depletion of BAG3 
had similar effects on some signaling pathways as depletion of HSP70 (e.g. on FoxM1 or 
HIF1), in other cases, depletion of BAG3 did not affect signaling but was necessary for 
HSP70 effects (e.g. with NF-kB or SRC). Therefore, in control of signaling pathways by 
BAG3-HSP70 pair each individual target may be subject to specific regulatory 
mechanisms. Although more work is needed, we suggest that these differences could be 
related to specific ways in which the signaling modules interact with BAG3. For 
example, while the BAG3 regulation of SRC is mediated by the PxxP domain, the 
interaction with other pathways could be through the WW or M-domains. 
We undertook several unbiased and biased approaches to dissect cancer-related 
pathways regulated by the HSP70-BAG3 module. We observed that HSP70-BAG3 
control activities of multiple signaling factors that are involved in cancer development. 
120 
 
 
The number of the factors was relatively large, consistent with a broad “hub” role for 
HSP70 in cancer. We validated a subset of these pathways, and found that HSP70 
depletion down-regulates HIF1 and FoxM1, while up-regulating NF-κB pathways. 
Interestingly, the former effects would presumably be anti-cancerous, while the latter is 
likely to be cancer-promoting. These disparate responses to the same stimulus should not 
be very surprising because similar phenomena have been observed with other anti-cancer 
treatments. For example, radiation triggers anti-cancer p53 pathway and also cancer-
promoting NF-κB and c-Abl (Chen et al, 2002; Meltser et al, 2011). In this case and in 
the case of HSP70 depletion, the net effect is anti-cancerous. 
Previously, HSP70 knockout was shown to prevent development of Her2-positive 
tumors in a mouse model by suppressing OIS (Meng et al, 2011), indicating that HSP70 
plays an important role at the early stages of tumor development. Our findings that the 
HSP70-BAG3 module affects pathways that regulate angiogenesis and invasion (e.g. 
HIF1 or FoxM1), suggest that HSP70 may play a broader role in cancer development. 
Indeed, while this has been reported that HSP70 is seen at elevated levels in low grade 
tumors (Ciocca & Calderwood, 2005) curiously, the levels of HSP70 increase further in 
high grade cancers (Kalogeraki et al, 2007; Rohde et al, 2005a), consistent with distinct 
role(s) of HSP70 in later stages of cancer progression, e.g. invasion. 
Overall, this work pointed to a key role for the HSP70-BAG3 complex in cancer, 
and suggests that this pair may represent a promising drug target. Of the available HSP70 
inhibitors, YM-1 is a unique probe because it specifically traps the ADP-bound form of 
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HSP70  (Rousaki et al, 2011). These observations suggested to us that YM-1 might block 
the HSP70-BAG3 interaction because BAG3 has a weak affinity for the ADP-bound 
form of HSP70 and it normally favors client release (Gestwicki, manuscript in 
preparation). Thus, although the known binding site for YM-1 is more than 20Å from the 
contact surface between HSP70 and BAG3, allosteric regulation of HSP70 by YM-1 
would be predicted to interrupt NEF binding. Accordingly, YM-1 has a mechanism of 
action that is unique among the known HSP70 inhibitors, which positions it to destabilize 
HSP70-BAG3 activities in cancer cells, leading to suppression of cancer-promoting 
signaling pathways.  Indeed, YM-1 had anti-cancer activity in cells and in a xenograft 
model. These results validate the HSP70-BAG3 complex as a potential anti-cancer target. 
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